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ABSTRACT
As growing numbers of students with attention deficit hyperactivity disorder
(ADHD) pursue postsecondary education, the availability of psychostimulant
medications on college campuses has steadily increased. Although a large body of
research has documented that misuse of prescription stimulant medication is a
prevalent problem on American college campuses, few studies have been conducted
beyond the United States. Iceland, closely followed by the United States, has the
highest stimulant medication prescription rates in the world; however, no systematic
efforts have been made to investigate to what extent these medications are being
misused within the Icelandic college student population. Therefore, the purpose of the
present study was to: a) examine the prevalence of prescription stimulant misuse
among N=521 college students in Iceland as well as factors that are potentially
predictive of stimulant misuse, including ADHD symptomatology, symptoms of
depression, anxiety, and stress, self-reported grade-point average (GPA), and student
sex; and b) identify the prevalence of significant ADHD symptomatology within this
population.
Results revealed the prevalence of lifetime stimulant misuse behavior was
approximately 13% within the overall sample, 11% among participants without a
prescription for stimulant medication, and 42% among participants holding a
prescription. The primary reported reason for misuse was academic enhancement,
similar to findings from the United States and Europe. Findings also suggested risk
factors for prescription stimulant misuse among college students in Iceland included
male sex, anxiety symptoms, and a history of ADHD symptoms. Approximately 8%

of participants reported persistent, elevated ADHD symptomatology, while
approximately 9% reported a previous diagnosis of ADHD.
The present findings have implications for public health policy in Iceland,
particularly as it relates to the college population. Limitations of the study and
suggestions for future research are discussed.

ACKNOWLEDGEMENTS
This dissertation would not have come to fruition without the help and support
of a wonderful group of people to whom I am deeply grateful. First, I wish to
acknowledge my major professor, mentor, and friend, Dr. Lisa Weyandt. Thank you
for introducing me to the current topic, for always providing prompt, constructive
feedback regarding my work, and for constantly enhancing my critical thinking and
writing skills. Thank you for taking me on as your student, for being a source of
inspiration, and for providing me countless opportunities to grow as a researcher,
school psychologist, and human being. Thank you for your kindness and generosity
and for being so exceptional.
I also wish to recognize Dr. Lisa Harlow. Thank you for everything you have
taught me, for your guidance and support, for being an outstanding instructor and
mentor, and for cheering me on with your positivity and enthusiasm. I am very
grateful to Dr. Alycia Mosley Austin for graciously agreeing to serve on my doctoral
committee at the last minute; thank you for your constructive feedback and helpful
contributions. To Dr. Susan Loftus-Rattan: thank you for your thoughtful comments
and support, and for kindly agreeing to serve on my committee. To Dr. Susan Brand;
thank you also for serving on my committee, for your insightful contributions and our
many stimulating conversations.
I would like to express my sincere gratitude to my friend and colleague: Thank
you, Sigrún Daníelsdóttir, for going above and beyond by serving as the guarantor of
the study and liaison with the National Bioethics Committee of Iceland, and for

iv

facilitating the data collection process. Without you and your tremendous help, this
study would not have been possible.
To the Icelandic college students who participated in the present study: I
greatly appreciate your time and contribution to this project. Thank you for making
this study a reality.
My fellow graduate students have been tireless in their support during our time
together at URI, especially (in alphabetical order) Dr. Marisa Marraccini, Danielle
Oster, Emma Rathkey, Lily E. H. Stella, Stephanie Tang, and Dr. Bryn Martinez
Zavras. I have learned so much from each of you. Thank you for your friendship and
for making our graduate journey so enjoyable. Drs. Susan Brady, Jaime Dice, Gary
Stoner, and Grant Willis have generously provided their advice and support during my
time at URI – thank you for everything you have done.
To Dr. Lou Ruffolo: Thank you for taking me on as your intern, for reminding
me why I chose to become a school psychologist, and for teaching me something new
every day. Thank you also for encouraging me to defend and complete this
dissertation in a timely manner. You are a phenomenal school psychologist and
mentor.
I am truly blessed with the most wonderful family and friends in Iceland: to
my late mother, Elín, my father, Guðmundur Þór, his wife, Eyrún, my stepmother,
María, my grandmother, Bergljót, my sister, Kolbrún María, my brothers, Kristján Páll
and Óskar, my cousin and friend, Helga Theodóra, my family-in-law, Ingibjörg,
Sigurður, and Steinunn, and my friends, Gabríela Bryndís and Ingibjörg: each and
every one of you has been an endless source of support, strength, and love. Thank you

v

for always being there for me, through thick and thin. Without you, I would not have
made it this far.
Lastly, I would like to express my deepest gratitude to my partner and best
friend, Ragnar. Thank you for embarking on this adventure with me, and for your
unflinching support, flexibility, encouragement, patience, and love. Thank you for
being my voice of reason and for being the extraordinary person you are.

vi

DEDICATION
To my mother, Elín Davíðsdóttir Greason (1962 – 2014)

vii

PREFACE
This dissertation is in manuscript format.

viii

TABLE OF CONTENTS

ABSTRACT ................................................................................................................... ii
ACKNOWLEDGEMENTS .......................................................................................... iv
DEDICATION ............................................................................................................. vii
PREFACE ................................................................................................................... viii
TABLE OF CONTENTS .............................................................................................. ix
LIST OF TABLES ........................................................................................................ xi
LIST OF FIGURES ..................................................................................................... xii
Publication Status ........................................................................................................... 1
Introduction .................................................................................................................... 2
Use and Misuse of Prescription Stimulants ................................................................ 4
Predictors of Prescription Stimulant Misuse .............................................................. 9
International Studies on Prescription Stimulant Misuse in College ......................... 11
Use of Prescription Stimulants in Iceland ................................................................ 12
Purpose of the Study .................................................................................................... 15
Research Hypotheses ................................................................................................... 16
Method ......................................................................................................................... 17
Procedure .................................................................................................................. 17
Participants ............................................................................................................... 18
Measures ................................................................................................................... 19
Demographics Questionnaire. ............................................................................... 19
DSM-IV Checklist of Symptoms.......................................................................... 19
The Depression Anxiety Stress Scale -21 (DASS-21).......................................... 20
Stimulant Survey Questionnaire-I (SSQ-I). .......................................................... 20
Results .......................................................................................................................... 22
Data Analyses ........................................................................................................... 22
Missing Data ............................................................................................................. 24
Psychometric Analyses ............................................................................................. 24
Icelandic Translation of the SSQ. ......................................................................... 24
DASS-21 and DSM-IV Checklists of Symptoms. ................................................ 27
Prevalence of Prescription Stimulant Misuse Behavior ........................................... 27
Group Differences based on History of Stimulant Misuse ....................................... 30
Factors Predictive of Prescription Stimulant Misuse ............................................... 31
Prevalence of Significant ADHD Symptomatology................................................. 33
Additional Post Hoc Analyses .................................................................................. 35
ix

Discussion .................................................................................................................... 37
Psychometric Findings ............................................................................................. 37
Prescription Stimulant Misuse Findings: Prevalence and Motivations .................... 38
Group Differences based on Stimulant Misuse History ........................................... 41
Factors Predictive of Prescription Stimulant Misuse ............................................... 42
ADHD Symptomatology Findings ........................................................................... 45
Additional Post Hoc Findings .................................................................................. 48
Limitations and Future Directions ............................................................................... 49
Conclusion ................................................................................................................... 50
References .................................................................................................................... 52
Appendix A .................................................................................................................. 95
Informed Consent (English) ..................................................................................... 95
Informed Consent (Icelandic) ................................................................................... 97
Appendix B .................................................................................................................. 99
Debriefing (English) ................................................................................................. 99
Debriefing (Icelandic) ............................................................................................ 100
Appendix C ................................................................................................................ 101
Statement on Diversity in Research ....................................................................... 101
Appendix D ................................................................................................................ 102
Demographic Questionnaire (English) ................................................................... 102
Demographic Questionnaire (Icelandic) ................................................................. 104
Appendix E ................................................................................................................ 106
DSM-IV Checklist of Symptoms – Past 6 Months (English)................................. 106
DSM-IV Checklist of Symptoms – Childhood (English)....................................... 107
DSM-IV Checklist of Symptoms – Past 6 Months (Icelandic) .............................. 108
DSM-IV Checklist of Symptoms – Childhood (Icelandic) .................................... 109
Appendix F ................................................................................................................. 110
Depression Anxiety Stress Scale -21 (DASS-21) .................................................. 110
Appendix G ................................................................................................................ 112
Stimulant Survey Questionnaire (English) ............................................................. 112
Stimulant Survey Questionnaire (Icelandic) .......................................................... 114

x

LIST OF TABLES
Table 1. Participant demographics .............................................................................. 68
Table 2. Initial, 8-component PCA with Varimax rotation .......................................... 69
Table 3. Final, 7 component PCA with Varimax rotation ........................................... 71
Table 4. SSQ Components, eigenvalues, and % of variance explained ....................... 73
Table 5. Correlation matrix for the 7 components of the Icelandic translation of the
SSQ among participants without a current prescription ............................................. 74
Table 6. Prevalence of stimulant misuse behaviors ..................................................... 75
Table 7. Percentage of students who responded “agree” or “strongly agree” to
statements concerning prescription stimulant use and availability ............................. 76
Table 8. Percentage of participants who responded “YES” to statements concerning
prescription stimulant misuse ...................................................................................... 77
Table 9. Descriptive statistics and independent t-test analyses for SSQ, DASS-21, and
DSM-IV Checklist scores for participants without a current prescription by stimulant
misuse history status .................................................................................................... 78
Table 10. SSQ Use of Stimulants for Academic, Cognitive, Physical, and Social
Enhancement, and Use of Stimulants for Partying or Getting High Pearson
correlations with DASS subscales (depression, anxiety, and stress), ADHD total
scores in childhood and adulthood, participant sex, and self-reported GPA .............. 79
Table 11. Regression analyses with Use of Stimulants for Academic, Cognitive,
Physical, or Social Enhancement component of SSQ as the dependent variable ........ 80
Table 12. Regression analyses with Use of Stimulants for Partying or Getting High
component of SSQ as the dependent variable .............................................................. 81

xi

LIST OF FIGURES
Figure 1. Regression model with Sex as the IV and Use of Stimulants for Academic,
Cognitive, Physical, or Social Enhancement as the DV: Assessment of independence of
errors assumption ........................................................................................................ 82
Figure 2. Regression model with Sex as the IV and Use of Stimulants for Academic,
Cognitive, Physical, or Social Enhancement as the DV: Assessment of independence of
errors assumption ........................................................................................................ 82
Figure 3. Regression model with Sex as the IV and Use of Stimulants for Academic,
Cognitive, Physical, or Social Enhancement as the DV: Assessment of normal
distribution assumption ................................................................................................ 83
Figure 4. Regression model with Sex as the IV and Use of Stimulants for Partying or
Getting High as the DV: Assessment of independence of errors assumption .............. 83
Figure 5. Regression model with Sex as the IV and Use of Stimulants for Partying or
Getting High as the DV: Assessment of homogeneity of variance and linearity
assumption ................................................................................................................... 84
Figure 6. Regression model with Sex as the IV and Use of Stimulants for Partying or
Getting High as the DV: Assessment of normal distribution assumption .................... 84
Figure 7. Regression model with GPA as the IV and Use of Stimulants for Academic,
Cognitive, Physical, or Social Enhancement as the DV: Assessment of independence of
errors assumption ........................................................................................................ 85
Figure 8. Regression model with GPA as the IV and Use of Stimulants for Academic,
Cognitive, Physical, or Social Enhancement as the DV: Assessment of homogeneity of
variance and linearity assumption ............................................................................... 85
Figure 9. Regression model with GPA as the IV and Use of Stimulants for Academic,
Cognitive, Physical, or Social Enhancement as the DV: Assessment of normal
distribution assumption ................................................................................................ 86
Figure 10. Regression model with GPA as the IV and Use of Stimulants for Partying
or Getting High as the DV: Assessment of independence of errors assumption ......... 86
Figure 11. Regression model with GPA as the IV and Use of Stimulants for Partying
or Getting High as the DV: Assessment of homogeneity of variance and linearity
assumption ................................................................................................................... 87
Figure 12. Regression model with GPA as the IV and Use of Stimulants for Partying
or Getting High as the DV: Assessment of normal distribution assumption ............... 87
Figure 13. Regression model with DASS subscales as the IV and Use of Stimulants for
Academic, Cognitive, Physical, or Social Enhancement as the DV: Assessment of
independence of errors assumption ............................................................................. 88
Figure 14. Regression model with DASS subscales as the IV and Use of Stimulants for
Academic, Cognitive, Physical, or Social Enhancement as the DV: Assessment of
homogeneity of variance and linearity assumption ..................................................... 88
xii

Figure 15. Regression model with DASS subscales as the IV and Use of Stimulants for
Academic, Cognitive, Physical, or Social Enhancement as the DV: Assessment of
normality assumption ................................................................................................... 89
Figure 16. Regression model with DASS subscales as the IV and Use of Stimulants for
Partying or Getting High as the DV: Assessment of independence of errors
assumption ................................................................................................................... 89
Figure 17. Regression model with DASS subscales as the IV and Use of Stimulants for
Partying or Getting High as the DV: Assessment of homogeneity of variance and
linearity assumption ..................................................................................................... 90
Figure 18. Regression model with DASS subscales as the IV and Use of Stimulants for
Partying or Getting High as the DV: Assessment of normality assumption ................ 90
Figure 19. Regression model with DASS subscales and ADHD symptoms as the IV and
Use of Stimulants for Academic, Cognitive, Physical, and Social Enhancement as the
DV: Assessment of independence of errors assumption .............................................. 91
Figure 20. Regression model with DASS subscales and ADHD symptoms as the IV and
Use of Stimulants for Academic, Cognitive, Physical, and Social Enhancement as the
DV: Assessment of homogeneity of variance and linearity assumption ...................... 91
Figure 21. Regression model with DASS subscales and ADHD symptoms as the IV and
Use of Stimulants for Academic, Cognitive, Physical, and Social Enhancement as the
DV: Assessment of normality assumption .................................................................... 92
Figure 22. Regression model with DASS subscales and ADHD symptoms as the IVs
and Use of Stimulants for Partying or Getting High as the DV: Assessment of
independence of errors assumption ............................................................................. 92
Figure 23. Regression model with DASS subscales and ADHD symptoms as the IVs
and Use of Stimulants for Partying or Getting High as the DV: Assessment of
homogeneity of variance and linearity assumption ..................................................... 93
Figure 24. Regression model with DASS subscales and ADHD symptoms as the IV and
Use of Stimulants for Partying or Getting High as the DV: Assessment of normality
assumption ................................................................................................................... 93
Figure 25. Distribution of scores on the Use of Prescription Stimulants for Academic,
Cognitive, Physical, or Social Enhancement component of the SSQ ........................... 94
Figure 26. Distribution of scores on the Use of Prescription Stimulants for Partying or
Getting High component of the SSQ ............................................................................ 94

xiii

Publication Status
This manuscript will be submitted for publication in Experimental and Clinical
Psychopharmacology.

Prescription Stimulant Misuse and ADHD Symptomatology among College
Students in Iceland

Corresponding Author: Bergljot Gyda Gudmundsdottir, M.A.
Department of Psychology
University of Rhode Island
Kingston, RI 02881
Email: gydagudmundsdottir@gmail.com

1

Introduction
Attention deficit hyperactivity disorder (ADHD) is a chronic disorder characterized by
clinically significant levels of inattention, hyperactivity, and impulsivity that causes
impairment in multiple settings. The disorder is estimated to affect approximately 5%
of children (Polanczyk, de Lima, Horta, Biederman, & Rohde, 2007) and 2.5% of
adults (Simon, Czobor, Bálint, Mészáros, & Bitter, 2009) across cultures (American
Psychiatric Association, 2013). Youth with ADHD often demonstrate various
problems in the school environment, such as difficulty remaining focused and seated,
disorganization, talking excessively, as well as noncompliance and aggression
(Danforth, Connor, & Doerfler, 2014; Pliszka, 2014). Due to these difficulties,
students with ADHD tend to perform more poorly than their peers academically (e.g.,
receive lower grades, repeat grades, drop out of high school at higher rates, [DuPaul &
Jimerson, 2014; Faraone et al., 1993]), and are less likely to attend and graduate from
college (Kuriyan et al., 2013). Despite this poor prognosis, increasing numbers of
students with ADHD are successfully completing high school and pursuing higher
education (DuPaul & Weyandt, 2009; Weyandt & DuPaul, 2013). While no definitive
information is available regarding the prevalence of ADHD in the college population,
given that the privacy of students with disabilities is protected under the Americans
with Disabilities Act (1991) and that ADHD may be underdiagnosed among college
students (Wolf, Simkowitz, & Carlson, 2009), studies estimate that 2-8% of college
students across cultures have significant ADHD symptoms (DuPaul et al., 2001;
Eagan et al., 2014; McKee, 2008; Weyandt, Linterman & Rice, 1995), and
approximately 18%-50% of students who receive disability accommodations in U.S.
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colleges do so primarily due to ADHD (Raue & Lewis, 2011; Wolf et al., 2009).
Weyandt and DuPaul (2013), leading researchers in the field, emphasized the paucity
of information available and stressed the need for studies to explore the prevalence
and nature of ADHD among college students as well as their academic and social
functioning. The extant literature has revealed, however, that college students with
ADHD and elevated ADHD symptomatology tend to exhibit academic
underachievement (Weyandt et al., 2013a), including lower GPAs (Advokat, Lane, &
Luo, 2011; Gormley et al., 2015), poorer study habits and study skills (Gormley et al.,
2015), greater difficulty with academic adjustment (Norwalk, Norvilitis, & MacLean,
2009; Rabiner, Anastopoulos, Costello, Hoyle, & Swartzwelder, 2008; Weyandt et al.,
2013a), and are more likely to drop out of college (Barkley, Murphy, & Fischer, 2008)
than their non-affected counterparts. College students with ADHD also generally
report more psychosocial difficulties, including a lower self-esteem (Canu & Carlson,
2007; Shaw-Zirt, Popali-Lehane, Chaplin, & Bergman, 2005), lower life satisfaction
(Gudjonsson, Sigurdsson, Eyjolfsdottir, Smari, & Young, 2009), higher levels of
internalizing and externalizing pathology (e.g., depression, anxiety, and hostility), and
greater executive dysfunction, compared to students without ADHD (Weyandt et al.,
2013a). More recently, Anastopoulos and colleagues (in press) reported that college
students with rigorously defined ADHD were significantly more likely than their nonaffected peers to meet diagnostic criteria for one or more comorbid psychiatric
disorder, particularly depression and anxiety. In fact, 55% of the ADHD participants
in this study presented with at least one comorbid diagnosis, compared with only 11%
of the non-ADHD sample. Taken together, this body of research clearly indicates that

3

students with significant ADHD symptoms face numerous challenges during the
college years. These findings underscore the need for identifying college students with
attention problems so that effective treatments may be implemented to help promote
their academic success and well-being.
Use and Misuse of Prescription Stimulants
The main treatment options for adults with ADHD include pharmacological
and psychosocial approaches with stimulant medication commonly recommended as
part of an individually tailored treatment plan (Kooij et al., 2010; National Institute for
Health and Clinical Excellence, 2009). Methylphenidate (MPH; e.g., Ritalin,
Concerta) and amphetamine (AMP; e.g., Adderall, Dexedrine) are the two most
commonly prescribed stimulants for the treatment of ADHD (Meijer et al., 2009;
Wilens, 2008), and are similar, although not identical, with respect to their presumed
neurochemical mode of action. Specifically, research with humans and other animals
indicates that MPH increases the availability of dopamine in the extracellular space by
blocking the dopamine transporter, thereby preventing dopamine reuptake (Weyandt,
2006). Additionally, MPH has been hypothesized to increase norepinephrine
availability by blocking the norepinephrine transporter (Berridge & Devilbiss, 2011).
AMP, however, is not only believed to prevent dopamine reuptake, but also to
stimulate its efflux from the presynaptic neuron, further increasing dopamine
availability. At higher doses, AMP also appears to stimulate norepinephrine efflux
(Berridge & Devilbiss, 2011; Weyandt, 2006).
Although no definitive pathophysiological profile has been documented in
ADHD, current neurobiological theories posit that catecholaminergic
4

neurotransmission plays an important role (Faraone & Biederman, 1998), particularly
in the fronto-striatal pathway (Wilens, 2008). Specifically, dysregulation of
neurotransmission in fronto-subcortical circuits has been associated with problems
with attention, motor behavior, and executive function, all of which are associated
with ADHD (although not uniquely so). Treatment with stimulant medication, in turn,
is believed to enhance catecholaminergic functioning in these areas, as manifested by
ADHD symptom improvement (del Campo et al., 2013; Engert & Pruessner, 2008;
Faraone & Biederman, 1998). Previously, prescription stimulants were believed to
primarily benefit individuals with ADHD; more recent evidence indicates, however,
these medications may enhance various physiological and cognitive processes in
individuals without ADHD as well (del Campo et al., 2013; Smith & Farah, 2011).
Beyond the presumed basic neurochemical actions of prescription stimulants,
the precise effects of these medications on brain function remain poorly understood.
Converging evidence supports, however, that when used as prescribed, stimulant
medications are safe and effective at improving core ADHD symptoms of inattention,
impulsivity, and hyperactivity, as well as improving psychological, cognitive, and
social functioning (Adler, Spencer, McGough, Jiang, & Muniz, 2009; Adler et al.,
2013; Brams, Giblin, Gasior, Gao, & Wigal, 2011; DuPaul et al., 2012; Faraone,
Spencer, Aleardi, Pagano, & Biederman, 2004; Retz et al., 2012; Spencer, Adler,
Weisler, & Youcha, 2008). Additionally, recent evidence indicates pharmacotherapy
with stimulants may serve as a protective factor among individuals with ADHD as
stimulants have been associated with decreased risk of substance abuse (Chang et al.,
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2014; Wilens, Faraone, Biederman, & Gunawardene, 2003) as well as lower risk of
suicidal behavior (Chen et al., 2014).
Despite major benefits for individuals with ADHD, prescription stimulants
also have been associated with more negative outcomes, including a variety of side
effects (e.g., sleep difficulties, reduced appetite, nausea, abdominal pain, headache,
and cardiac symptoms [Craig, Davies, Schibuk, Weiss, & Hechtman, 2015; Weyandt
et al., 2014]) and significant potential for misuse that can possibly lead to
psychological and/or physiological dependence (Kollins, 2003), as reflected by their
classification as Schedule II medications by the U.S. Food and Drug Administration
(2011). As increasing numbers of individuals with ADHD pursue college, the nonmedical use of prescription stimulants has become more evident on college campuses,
and has been well documented in the literature (Benson, Flory, Humphreys, & Lee,
2015; Weyandt et al., 2013b). Indeed, many college students claim that stimulant
medications are easily accessible on campus (McCabe, Knight, Teter & Wechsler,
2005; Rabiner et al., 2009; Sharp & Rosen, 2007; Weyandt et al., 2009), and
stimulants are usually obtained from other students with a valid prescription (Benson
et al., 2015; Weyandt et al., 2013b).
The non-medical use or misuse of stimulants, usually defined as taking
stimulants without a valid prescription or greater use of stimulants than as prescribed
(Benson et al., 2015; Weyandt et al., 2013b), has soared among university students
since the beginning of the century (Babcock & Byrne, 2000; DeSantis, Noar, &
Webb, 2010; DuPont, Coleman, Bucher, & Wilford, 2008; Dussault & Weyandt,
2013; Hall, Irwin, Bowman, Frankenberger, & Jewett, 2005; Janusis & Weyandt,
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2010; Judson & Langdon, 2009; Low & Gendaszek, 2002; Messina et al., 2014;
McCabe et al., 2005; McCabe, West, Teter, & Boyd, 2014; Rabiner et al., 2009; Sharp
& Rosen, 2007; Verdi, Weyandt, & Zavras, 2014; Weyandt et al., 2009; White,
Becker-Blease & Grace-Bishop, 2006). For example, Babcock and Byrne reported a
lifetime prevalence rate of stimulant misuse behavior of 16.6% among college
students in the year 2000 whereas in 2014 Messina and colleagues reported a lifetime
prevalence rate of 25.4%. Other studies have reported a lifetime prevalence rate as
high as 43% (DeSantis, Webb, & Noar, 2008). Recently, Benson and colleagues
(2015) conducted a meta-analysis of 20 studies in which they estimated the prevalence
rate of stimulant misuse to be at 17% among college students (95% confidence
interval [CI] [13%, 23%]). Regardless of exact prevalence rates, studies consistently
indicate that a large percentage of college students have misused prescription
stimulants. Given the judicial and potential health risks associated with the misuse of
prescription stimulants, several studies have attempted to shed light on the motivations
for engaging in this behavior.
A systematic review of the literature conducted by Weyandt and colleagues
(2013) revealed that several reasons for misusing prescription stimulants have been
reported, chief among them being cognitive and academic enhancement. More
specifically, college students who disclose engaging in stimulant misuse report doing
so while studying (e.g., preparing for exams, writing papers) to increase their attention
and alertness, and thus improve their academic performance. Rabiner and colleagues
(2009) also found that although a number of reasons for misuse were reported in their
study, the most strongly endorsed reasons pertained to the enhancement of academic
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performance. Interestingly, however, stimulant misuse has been found to be negatively
associated with academic functioning (Benson et al., 2015), which suggests that
contrary to what students believe, presecription stimulants may not necessarily lead to
improved academic performance. Weyandt et al. (2013b) as well as Benson et al.
(2015) reported other less commonly endorsed reasons for the non-medical use of
stimulants include “getting high”, staying awake to party, extending the effects of
alcohol or other substances, losing weight, and curiosity, and up to 40% of students
appear to misuse stimulants for both academic and non-academic reasons (Benson et
al., 2015). According to Weyandt et al. (2013b), the most common method of
stimulant administration among those who misuse is oral, followed by intranasal
administration, but a small percentage of students report either smoking or injecting
them. Finally, Benson et al. (2015) and Weyandt and colleagues (2013b) reported that
most students engaging in misuse of prescription stimulants report obtaining the drugs
from other students, and to a lesser extent from family members; and students have
also reported stealing the medications from others and overusing their own
prescriptions.
To summarize, the misuse of prescription stimulants has increased
substantially in the past two decades among college students. In addition to examining
the prevalence, motivations, and characteristics of stimulant misuse, researchers also
have sought to identify specific predictors of this behavior, including both
demographic and psychological variables.
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Predictors of Prescription Stimulant Misuse
Preliminary studies have identified several demographic variables that are
predictive of prescription stimulant misuse. For example, results from a number of
studies have indicated males are more likely to engage in stimulant misuse than
females, although findings have been inconsistent (Benson et al., 2015; Weyandt et al.,
2013b). Weyandt et al. (2013b) calculated the magnitude of sex differences in studies
examining the non-medical use of stimulants and found Cohen’s d effect sizes ranging
from .88 to 5.38, suggesting stark group differences favoring males. In terms of
race/ethnicity, some studies have found students identifying as white or Caucasian are
more likely to endorse stimulant misuse than students of non-white backgrounds,
whereas others have reported no significant differences across racial/ethnic groups
(Benson et al., 2015). As stated previously, academic performance, usually measured
by self-reported grade point average (GPA), has been found to be negatively
associated with misuse of prescription stimulants across several studies (Benson et al.,
2015). For example, Arria, O’Grady, Caldeira, Vincent, and Wish (2008) reported that
first-year college students who misused prescription stimulants had lower high school
GPAs, attended classes less frequently, devoted less time to studying, and spent more
time socializing compared to nonusers. Furthermore, results indicated that past-year
non-medical use of stimulants predicted lower GPA by the end of the first year of
college, which was mediated by skipping class.
With regard to psychological risk factors, depression (Huang et al., 2006;
Teter, Falone, Cranford, Boyd & McCabe, 2010; Zullig & Divin, 2012), anxiety
(Dussault & Weyandt, 2013; Verdi et al., 2014; Weyandt et al., 2009), stress (Dussault
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& Weyandt, 2013; Peterkin, Crone, Sheridan, & Wise, 2011; Verdi et al., 2014), and
internal restlessness (Dussault & Weyandt, 2013, Verdi et al., 2014; Weyandt et al.,
2009) have all been found to be predictive of stimulant misuse. Notably, internal
restlessness has been conceptualized as the adult manifestation of childhood
hyperactivity; that is, symptoms of physical hyperactivity in childhood are often
replaced with cognitive, mental, or internal restlessness as individuals enter adulthood
(Biederman, Mick, & Faraone, 2000; Weyandt et al., 2003). Consequently, some
researchers have speculated that students who misuse stimulants may be “selfmedicating” to treat symptoms of ADHD. For instance, Rabiner et al. (2009) found
that ADHD symptoms of inattention significantly predicted misuse of prescription
stimulants, even after controlling for use of other substances. In contrast, symptoms of
hyperactivity/impulsivity were associated with greater odds of engaging in other
substance use. Similarly, Arria and colleagues (2011) found that untreated symptoms
of inattention were associated with persistent misuse of stimulants. Finally, Benson
and colleagues’ (2015) meta-analytic review suggested having a diagnosis of ADHD
is significantly associated with stimulant misuse, with odds ratios ranging from 1.02 to
21.44. Collectively, these findings suggest ADHD symptoms likely constitute a risk
factor for stimulant misuse.
In summary, studies clearly indicate prescription stimulant misuse is a
prevalent problem on American college campuses. The primary reason students report
for engaging in such misuse is enhancement of cognitive and academic performance.
Research, however, presents a different picture, given that misuse of stimulants
appears to be negatively associated with academic performance, and positively
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associated with various psychological difficulties, including symptoms of ADHD,
depression, anxiety, and stress. Preliminary evidence from other countries indicates
prescription stimulant misuse is not unique to North American college life; however,
information concerning stimulant misuse behavior among college students in other
countries is scarce.
International Studies on Prescription Stimulant Misuse in College
Studies regarding prescription stimulant misuse beyond the United States are
scant. An investigation conducted by Deline and colleagues (2014) in Switzerland
concerning the use of various neuroenhancement drugs, including prescription
stimulants, among males, revealed that while misuse was much lower than in the
United States (i.e., 3%), prescription stimulants were the most frequently misused
drugs. Furthermore, in this sample, college students reported less misuse of
prescription stimulants than did those not enrolled in college. Surprisingly, Deline et
al. (2014) did not find an association between ADHD status and misuse behavior;
however, they identified participants as either ADHD or non-ADHD using a cut-off
score based only on self-report ratings on a 6-item screening measure. Given the
limited rigor in Deline et al.’s (2014) assessment of ADHD symptoms the validity of
these findings is equivocal. Maier, Liechti, Herzig, and Schaub (2013) also
investigated stimulant misuse in Switzerland among over 6,000 university students of
whom 4.5% endorsed having used either MPH or AMP, primarily for academic and/or
cognitive enhancement. In this study, students who reported increased levels of stress
were significantly more likely to endorse misuse behavior, mirroring findings from the
United States linking psychological distress with stimulant misuse (e.g., Benson et al.,
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2015; Weyandt et al., 2009). A study by Mache, Eickenhorst, Vitzthum, Klapp, and
Groneberg (2012) regarding substance use among German university students
revealed that approximately 1-13% had used either prescription stimulants or illicit
psychoactive drugs (e.g., cannabis) at least once. Similar to American students, the
main reported motives for using these drugs were to improve concentration, increase
alertness, and relax. In another German study, Dietz and colleagues (2013) examined
the 12-month prevalence of the use of cognitive enhancement drugs among university
students, including amphetamines, caffeine tablets, cocaine, methylphenidate, and
mephedrone. Results suggested 20% of the students had used cognitive enhancers
within the past 12 months and that males were more likely than females to have used
such drugs.
The results of these studies indicate that European university students are
indeed using various substances, including prescription stimulants, to ostensibly
improve their attention and academic performance, much like their American
counterparts. Preliminary studies suggest the prevalence of misuse behavior in these
countries may be lower than in the United States; however, more detailed information
regarding this issue is needed.
Use of Prescription Stimulants in Iceland
Although limited data exist regarding misuse of prescription stimulants among
college students beyond the United States, research indicates that in terms of
prescription rates, Iceland, closely followed by the United States, has the highest per
capita overall consumption of prescription stimulants in the world among children,
adolescents, and adults, or 8-12 defined daily doses for statistical purposes (S-DDD),
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compared with 2-6 S-DDD in Canada, Switzerland, Sweden, and Norway, for example
(Kaye & Darke, 2012). Similarly, Zoëga and colleagues’ (2011) investigation of
stimulant use in the Nordic countries revealed the rate of prescriptions for stimulant
medications in Iceland was nearly 12 times that in Finland and almost five times that
in Sweden. Moreover, using data from the complete nationwide drug prescription
database in Iceland, Geirs, Pottegård, Halldórsson, and Zoëga (2014) reported the 1year period prevalence of overall prescription stimulant use tripled between 2003 and
2012, with the largest increases in prescription rates among young adults between the
ages of 19 and 24. No studies have been conducted to date, however, to specifically
examine the prevalence of ADHD in the Icelandic population. Despite widespread use
of ADHD medications in Iceland, only one study that examined prescription stimulant
misuse in Iceland was found, and included a group of individuals with chronic
substance abuse problems who used these medications mostly intravenously
(Bjarnadottir et al., 2013). Bjarnadottir and colleagues (2013) concluded that
prescription stimulant misuse is a growing problem in Iceland, at least among those
with addiction issues. In addition, the International Narcotics Control Board (INCB)
requested clarification from Icelandic authorities due to the high rates of stimulant
prescriptions to children, adolescents, and adults (The Icelandic Medical Journal,
2011).
Given the similarities between Iceland and the United States with respect to
stimulant prescription rates, the growing numbers of young adults prescribed stimulant
medications in Iceland, and the prevalence of stimulant misuse on American college
campuses, it is highly plausible these medications are also being misused among
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Icelandic college students. To date, however, no systematic efforts have been made to
evaluate the scope and nature of prescription stimulant misuse among college students
in Iceland, nor how the prevalence of ADHD symptomatology in this population
relates to such behavior. In light of the health and judicial risks associated with misuse
of prescription stimulants, it is critical to investigate the extent to which these
medications are being misused in Iceland as well as factors, such as ADHD
symptomatology, that are predictive of prescription stimulant misuse.
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Purpose of the Study
A voluminous body of research has assessed the prevalence, characteristics,
and predictors of prescription stimulant misuse among undergraduate students in the
United States. The results of these studies collectively indicate this behavior
constitutes a significant problem on American college campuses (Benson et al., 2015;
Weyandt et al., 2013b). Only a few studies, however, have assessed the prevalence of
prescription stimulant misuse beyond the United States. Prescription rates for
stimulant medications for ADHD are similar in Iceland and the United States;
however, in contrast to the United States, no studies have been conducted to assess the
prevalence of prescription stimulant misuse among college students in Iceland.
Therefore, the purpose of the present study was to explore the prevalence rates of
prescription stimulant misuse among Icelandic college students and to examine
potential predictors of this behavior. Such findings will be instrumental in the
development of prevention and intervention programs to help improve the outcomes of
college students who misuse prescription stimulants. For the purposes of the present
study, prescription stimulant misuse was defined as use of stimulant medications
without a valid prescription (e.g., Dussault & Weyandt, 2013; Verdi et al., 2014).
Specifically, the current study investigated: a) self-reported prevalence of prescription
stimulant misuse among Icelandic college students, and b) self-reported prevalence of
ADHD symptomatology as well as symptoms of depression, anxiety, and stress.
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Research Hypotheses
Based on previous empirical findings, it was hypothesized that:
1) Male sex would be more strongly associated with prescription stimulant
misuse behavior than female sex,
2) Self-reported GPA would be negatively associated with prescription
stimulant misuse,
3) Symptoms of depression, anxiety, and stress would be positively associated
with prescription stimulant misuse, and
4) ADHD symptomatology would significantly predict prescription stimulant
misuse while controlling for symptoms of depression, anxiety, and stress.
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Method
Procedure
The current study was approved by the National Bioethics Committee of
Iceland (reference number: VSNb2014050018/03.07) as well as the Institutional
Review Board (IRB) at the University of Rhode Island. University staff and faculty at
four universities in Iceland were contacted via email, and asked to assist with the
recruitment of undergraduate research participants. Two of the universities were
located in the capital region of Iceland, whereas the other two were located in more
rural areas. Specifically, contact people at each of the four universities were asked to
forward an email containing a brief summary of the study and a link to a secure online
survey website (SurveyMonkey) to all Icelandic undergraduate students who might be
eligible and willing to participate. To further facilitate participant recruitment, the
same information was posted on public Icelandic Facebook webpages. Before
initiating the online survey, potential participants were presented with an electronic
informed consent form (Appendix A) and instructed to confirm they had read and
understood the content by checking a statement of endorsement. The consent form
contained the researchers’ contact information should participants have had questions
or concerns and listed the requirements and responsibilities of participating in the
study, including a description of the research project (e.g., time commitment, potential
for harm, anonymity, etc.). Participants were made aware that the survey was
completely voluntary and anonymous and that they had the opportunity to discontinue
participation in the study at any time. Participants who provided consent to participate
were then directed to the study questionnaires. To encourage participation, potential
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participants were offered to enter a drawing at the end of the survey for a chance to
win a 5,000 ISK gift card (≈45 USD). Upon completion of the study questionnaires,
participants were debriefed and provided with information regarding how to contact
the researchers with any questions or concerns (see Appendix B).
Participants
A total of 931 individuals accessed the online survey; 929 agreed to participate
while 2 individuals declined participation. The present sample included N=521
participants of undergraduate status from the four largest universities in Iceland, n=34
of whom (6.5%) reported having a current prescription for psychostimulant
medication. The remaining 408 participants reported being of graduate student status
(n=102), did not disclose their status, and/or did not complete the entire survey
(n=306). Participants holding a current prescription for stimulant medication were
excluded from regression analyses concerning predictors of stimulant misuse
behavior, given the current study’s definition of misuse as use of stimulants without a
valid prescription. This subgroup of participants, however, was not excluded from
other analyses (e.g., psychometric analyses, prevalence rates of stimulant misuse
[although stimulant misuse prevalence rates were calculated separately for each group
based on prescription status], and prevalence of significant ADHD symptomatology
calculations).
The mean age of participants was 28.33 years (SD=8.36; range 19-57 years). A
majority of participants identified as female (81.4%), and 18.6% identified as male.
Based on available demographic information (Reykjavik University 2011; University
of Iceland, 2013), approximately 60% of participants were expected to be female;
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therefore, the gender distribution of the current sample was more unequal than
anticipated. As expected, a large majority of participants identified as white (99.2%),
compared with only 0.8% identifying as either non-white or other. Sixty-nine
participants (13.2%) endorsed having some form of a disability and 47 participants
(9%) reported a previous diagnosis of ADHD. Information concerning participant
demographics can be found in Table 1 and a statement regarding diversity in research
is presented in Appendix C.
Measures
Demographics Questionnaire. The demographics questionnaire included
questions about participant age, gender/sex, race/ethnicity, university, degree program,
cumulative grade point average (GPA), ADHD diagnostic status, and stimulant
medication prescription status. As stated previously, participants who reported having
a current prescription for stimulant medication were not excluded from participating in
the study but for regression analyses concerning stimulant misuse behavior their
responses were not included, given that the focus of the study was use of prescription
stimulants without a valid prescription. The demographic questionnaire is presented in
Appendix D.
DSM-IV Checklist of Symptoms.The DSM-IV Checklist of Symptoms
comprises 18 statements regarding symptoms of ADHD based on DSM-IV criteria
(APA, 1994), nine of which pertain to each symptom domain of inattention and
hyperactivity/impulsivity, respectively. Each statement is rated in terms of its
frequency of occurrence (0 = never, 1 = sometimes, 2 = often, 3 = very often).
Participants were asked to rate both current (preceding 6 months) and childhood (prior
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to the age of 12) symptom frequency. Magnússon et al. (2006) reported that the
Icelandic version of the DSM-IV Checklist of Symptoms demonstrated “excellent” (p.
501) reliability and validity in their sample, including strong correlations with welldefined childhood and adulthood ADHD. The DSM-IV Checklist of Symptoms is
presented in Appendix E.
The Depression Anxiety Stress Scale -21 (DASS-21). The DASS-21 (Lovibond
& Lovibond, 1995) comprises 21 items measuring levels of anxiety, depression and
stress among adults. Responses are provided on a 4-point Likert-scale to express the
extent to which each statement has applied to the respondent during the previous seven
days. Response options range from 0 to 3 (i.e., “did not apply to me at all” to
“applied to me very much/most of the time”; Lovibond & Lovibond, 1995). An
Icelandic version of the DASS-21 was used in the current study. Gudjonsson et al.
(2009) reported excellent internal consistency coefficients for the Icelandic version of
the DASS-21 in a sample of college students, with Cronbach’s alpha for the three
subscales and total score ranging between 0.86-0.95. Additionally, Ingimarsson (2010)
reported that the DASS-21 had acceptable convergent and discriminant validity. The
DASS-21 is presented in Appendix F.
Stimulant Survey Questionnaire-I (SSQ-I).The SSQ-I contains 40 items
(Weyandt et al., 2009) designed to assess misuse of prescription stimulants among
college students, as well as perceptions of and knowledge about prescription stimulant
use. Thirty items are statements to which participants respond on a 5-point Likert scale
(e.g., “never” to “always” or “strongly disagree” to “strongly agree”, as applicable).
Response options are presented in dichotomous format for the final 10 items (“yes” or
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“no”). For the original version of SSQ-I, a total score can be obtained by summing the
items although items also have been observed to load on four distinct factors: (1) Selfreported prescription stimulant use, (2) Perception of prevalence of prescription
stimulant use among peers, (3) Knowledge of atypical stimulant use among peers, and
(4) Perception of safety of stimulants (Weyandt et al., 2009). For the purposes of the
present study, an Icelandic translation of the SSQ was administered; given the lack of
information pertaining to its reliability, validity, and dimensionality, psychometric
analyses were conducted. The SSQ is presented in Appendix G.
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Results
Data Analyses
Preliminary psychometric analyses were conducted, including an assessment of
the internal consistency of each measure, as well as the factor structure of the newly
translated Icelandic version of the SSQ. Additionally, data were examined with regard
to assumptions of normality, linearity, and homoscedasticity. Prevalence rates of
stimulant misuse were assessed by calculating the percentage of students who
endorsed at least one form of prescription stimulant misuse behavior as having
occurred at least “rarely”, as measured by the Use of Stimulants for Academic,
Cognitive, Physical, or Social Enhancement, and Use of Stimulants for Partying or
Getting High components of the Icelandic version of the SSQ. The prevalence of
significant ADHD symptomatology was assessed by calculating the percentage of
students who earned total scores of at least 25 and 23 on the childhood and adulthood
versions of the DSM Checklist of Symptoms, respectively. Magnússon et al. (2006)
reported these cutoff scores have a sensitivity index of 0.80 and specificity of 0.90 for
detecting ADHD in childhood as well as adulthood.
Hypothesis 1, that male sex (independent variable; IV) would be more strongly
associated with prescription stimulant misuse than female sex, as measured by the Use
of Stimulants for Academic, Cognitive, Physical, or Social Enhancement and Use of
Stimulants for Partying or Getting High components of the Icelandic version of the
SSQ (dependent variables; DV), was tested via simple regression.
Hypothesis 2, that self-reported GPA (IV) would be negatively associated with
prescription stimulant misuse, as measured by the Use of Stimulants for Academic,
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Cognitive, Physical, or Social Enhancement and Use of Stimulants for Partying or
Getting High components of the Icelandic version of the SSQ (DV), was tested via
simple regression.
Hypothesis 3, that symptoms of depression, anxiety, and stress as measured by
the three corresponding subscales of the DASS-21 (IVs), respectively, would be
positively associated with prescription stimulant misuse, as measured by the Use of
Stimulants for Academic, Cognitive, Physical, or Social Enhancement and Use of
Stimulants for Partying or Getting High components of the Icelandic version of the
SSQ (DV), was tested via multiple regression.
Hypothesis 4, that symptoms of ADHD, as measured by scores on the DSM-IV
Checklist of Symptoms (IVs), would significantly predict prescription stimulant
misuse as measured by the Use of Stimulants for Academic, Cognitive, Physical, or
Social Enhancement and Use of Stimulants for Partying or Getting High components
of the Icelandic version of the SSQ (DV), while controlling for symptoms of
depression, anxiety, and stress (IVs), as measured by the three corresponding
subscales of the DASS-21 respectively, was tested using multiple regression.
Other analyses included examining differences in prescription stimulant
misuse between students with and without a prescription for stimulant medication
(descriptively), group differences in scores on the DASS-21 and DSM-IV Checklist of
Symptoms based on history of stimulant misuse, and group differences in scores on
the DASS-21 and SSQ based on significant ADHD symptomatology status as well as
self-reported disability status. Based on the results of a post hoc power analysis
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conducted in G*Power 3.2.1 (Faul, Erdfelder, Buchner, & Lang, 2009), the current
study had estimated power ranging between 0.72 – 0.99, depending on analysis.
Missing Data
At the individual item level, missing data ranged between 0.2% and 6%. As for
missing data patterns, the percentage of missing data was generally lower for items
administered earlier in the survey (e.g., the SSQ) compared to items administered later
in the survey (e.g., DASS-21, DSM-IV Checklist of Symptoms, Demographic
Questionnaire). Although no universal agreement exists concerning what percentage
of missing data should be regarded as problematic, estimates have ranged between 520% (Schlomer, Bauman, & Card, 2010). Missing data were handled using listwise
deletion.
Psychometric Analyses
Icelandic Translation of the SSQ. An exploratory principal components
analysis (PCA) of the Icelandic translation of the SSQ with Varimax rotation was
conducted. Responses from all participants, regardless of prescription status, were
included to obtain as large a sample as possible. It should be noted that items 35 and
36 of the original version of the SSQ were combined into a single item as their
meaning and content was virtually identical in the Icelandic translation. The Icelandic
version of the SSQ therefore included a total of 39 items, as opposed to 40.
Additionally, it should be noted that item 5 of the Icelandic version of the SSQ,
concerning injection of prescription stimulants, was impossible to include in the PCA
given that every participant endorsed this item as never having occurred (i.e., as “0”).
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Velicer’s MAP test and Horn’s parallel analysis were used to determine the
number of components (O’Connor, 2000), both of which suggested 8 components
should be extracted. The PCA (see table 2) revealed items 1, 6, 9, 19, 20, 38, and 39
had complex loadings; however, items 1, 6, 9, and 38 were retained given that they fit
well conceptually with at least one of the components on which they loaded. Although
items 19, 20, and 39 were not eliminated from the overall scale, they were not added
to any of the components identified by the PCA. Component 8 comprised three of the
complex items 6, 19, and 38, all of which were either added to other components due
to better conceptual fit, or excluded. Therefore, the eighth component was eliminated,
resulting in a total of 7 components. Another PCA with 7 components, excluding
items 5, 19, 20, and 39, was conducted (see table 3). Table 4 depicts the eigenvalues
and percentage of variance explained for each component.
Items 1, 9, and 10 were complex and loaded on components 1 and 2. Despite
their complexity, all three items were retained due to their importance in assessing
stimulant misuse behavior; item 1 was added to component 2 and items 9 and 10 to
component 1, due to higher component loadings and better conceptual fit. Similarly,
items 15 and 16 were also complex; however, they were both retained and added to
component 6 for optimal conceptual fit.
The overall internal consistency coefficient for all 39 items of the SSQ was
Cronbach’s alpha = 0.741. The 7 components were conceptualized and labeled as
follows:
1. Use of Stimulants for Academic, Cognitive, Physical, or Social Enhancement
(Cronbach’s alpha = .905);
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2. Use of Stimulants for Partying or Getting High (Cronbach’s alpha = 0.896);
3. Knowledge of Other Students’ Use of Stimulants (Cronbach’s alpha = 0.856);
4. Perceptions of Stimulant Availability (Cronbach’s alpha = .783);
5. Perceptions of Stimulant Safety (Cronbach’s alpha = 0.774);
6. Sharing Stimulants with Other Students (Cronbach’s alpha = 0.563); and
7. Perceived Knowledge about Stimulants (Cronbach’s alpha = 0.945).
All internal consistency coefficients for the SSQ as a whole, as well as its 7
components, ranged from acceptable to excellent with the exception of component 6,
Sharing Stimulants with Other Students (alpha = 0.563) which may partly stem from
relatively low component loadings for 2 out of the 4 items contributing to this
component, as illustrated in table 3. Together, the 7 components accounted for 65.4%
of the overall variance (see table 4).
Intercorrelational analyses for the 7 components of the SSQ, presented in table
5, revealed Use of Stimulants for Academic, Cognitive, Physical, or Social
Enhancement and Use of Stimulants for Partying or Getting High were significantly
and positively correlated (r = 0.52, p < 0.001). Additionally, Sharing Stimulants with
Other Students was significantly correlated with Use of Stimulants for Academic,
Cognitive, Physical, or Social Enhancement (r = 0.46, p < 0.001) and Use of
Stimulants for Partying or Getting High (r = 0.42, p < 0.001). Perceptions of Stimulant
Safety were significantly but modestly correlated with Use of Stimulants for
Academic, Cognitive, Physical, or Social Enhancement (r = 0.19, p < 0.001) as well as
Use of Stimulants for Partying or Getting High (r = 0.13, p = 0.004). Similarly,
Perceived Knowledge about Stimulants was only modestly correlated with Use of
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Stimulants for Academic, Cognitive, Physical, or Social Enhancement (r = 0.15, p =
0.001), but not Use of Stimulants for Partying or Getting High (r = 0.07, p = 0.11).
DASS-21 and DSM-IV Checklists of Symptoms. The Cronbach’s alphas for the
three subscales of the DASS-21 as well as the DASS-21 as a whole were excellent:
Depression = 0.921, Anxiety = 0.833, Stress = 0.873, DASS-21-Total = 0.942. In a
similar vein, the Cronbach’s alphas for the subscales and total score of the DSM
Checklist of Symptoms were excellent: Inattention Past 6 Months = 0.893,
Hyperactivity/Impulsivity Past 6 Months = 0.826, ADHD Total Past 6 Months =
0.913; Inattention Childhood = 0.936, Hyperactivity/Impulsivity Childhood = 0.931,
ADHD Total Childhood = 0.958.
Prevalence of Prescription Stimulant Misuse Behavior
Overall prevalence of lifetime prescription stimulant misuse, irrespective of
prescription status, was 13.2% (95% CI: [10.26%, 16.14%]). Specifically, lifetime
prevalence of a score of 1 or higher on Use of Stimulants for Academic, Cognitive,
Physical, or Social Enhancement was 10.1% (95% CI: [7.5%, 12.7%]) while
prevalence of a score of 1 or higher on Use of Stimulants for Partying or Getting High
was 10.9% (95% CI: [8.21%, 13.59%]).
Among those without a current prescription for prescription stimulant
medication, the overall prevalence of lifetime prescription stimulant misuse was
11.2% (95% CI: [8.34%, 14.06%]). The percentage of participants earning a score of
at least 1 or higher on the Use of Stimulants for Academic, Cognitive, Physical, or
Social Enhancement component of the SSQ was 8.1% (95% CI: [5.64%, 10.56%]).
With regard to the Use of Stimulants for Partying or Getting High component, the
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percentage of participants earning a score of at least 1 or higher was 10.2% (95% CI:
[7.47%, 12.93%]). Within the group of participants holding a current prescription, the
overall prevalence of lifetime prescription stimulant misuse was 42.4% (95% CI:
[25.79%, 59.01%]) The percentage of participants with a prescription earning a score
of at least 1 or higher on the Use of Stimulants for Academic, Cognitive, Physical, or
Social Enhancement component of the SSQ was 42.4% (95% CI: [25.79%, 59.01%]).
As for the Use of Stimulants for Partying or Getting High subscale, the percentage of
participants with a prescription earning a score of at least 1 or higher was 10.2% (95%
CI: [0.03%, 20.37%]).
Table 6 provides prevalence rates for each individual stimulant misuse
behavior, broken down by prescription status. As table 6 illustrates, the prevalence of
stimulant misuse behavior was generally higher among those currently holding a
prescription for stimulants compared to those without a prescription. An important
caveat, however, is the fact that the group currently holding a prescription for
stimulant medication was significantly smaller (n=34) than the group without a
prescription (n=487). Interestingly, 7.7% of the entire sample reported having been
offered prescription stimulants by other students; within the group without a current
prescription only 6.7% endorsed having been offered prescription stimulants by other
students whereas 17.6% of the group currently holding a prescription had been offered
such drugs by peers. Overall, the most commonly endorsed reasons for misusing
stimulants were to 1) perform better in schoolwork, 2) feel more energetic, 3) perform
better on tests, 4) focus better in class, and 5) to “get high”. In the group without a
prescription the most commonly endorsed reasons for misuse were as follows: to 1)

28

perform better in schoolwork, 2) feel more energetic, 3) “get high”, 4) perform better
on tests, and 5) focus better in class. Within the group currently holding a prescription
the following reasons emerged as the most commonly endorsed: to 1) perform better
in schoolwork, 2) perform better on tests, 3) focus better in class/feel more energetic,
4), socialize better, and 5) feel better about myself.
As can be seen in table 7, a small percentage (11-12%) of participants agreed
or strongly agreed that stimulants are easily accessible, regardless of prescription
status. The percentage of participants without a prescription agreeing or strongly
agreeing that stimulant use on campus is a problem was 14.5% while for participants
holding a prescription it was 8.8%. The group without a prescription generally felt
either neutral or disagreed that occasional or daily use of stimulants is harmless (7.4%
agreed or strongly agreed that occasional use is harmless; 1.9% agreed or strongly
agreed that daily use is harmless). In the group currently holding a prescription for
stimulant medication the percentage of participants agreeing or strongly agreeing that
such use is harmless was much higher (32.4% agreed or strongly agreed that
occasional use is harmless; 17.6% agreed or strongly agreed that daily use is
harmless).
Also evident from data presented in table 7, a considerable percentage of
students reported feeling knowledgeable about stimulants and their side effects, and
within the group holding a current prescription this percentage was approximately
double that of the group without a prescription (42% and 41.3% in the group without a
prescription compared with 76.5% and 85.3%, in the group with a prescription).

29

Table 8 illustrates the percentage of participants who agreed to statements
regarding prescription stimulant misuse. A large majority of students endorsed
knowing about other students who use stimulants for academic, cognitive, and
physical enhancement, as well as for recreational reasons (74% - 96% in the overall
group). Of students holding a prescription for stimulants, 55% reported hiding their
medication to prevent others from taking it.
Group Differences based on History of Stimulant Misuse
Table 9 includes the minimum and maximum values as well as the means and
standard deviations for each of the components/subscales of the SSQ, DASS-21, and
DSM-IV Checklist of Symptoms broken down by history of stimulant misuse among
participants without a current prescription for stimulant medication. Based on
descriptive data, all component/subscale means were higher in the group reporting a
history of stimulant misuse (i.e., among students earning a score of at least 1 on the
Use of Stimulants for Academic, Cognitive, Physical, or Social Enhancement or Use
of Stimulants for Partying or Getting High components of the SSQ), except for the
Knowledge of Other Students’ Use of Stimulants component of the SSQ. Independent
samples t-tests, also illustrated in table 9, revealed scores on the Knowledge of Other
Students’ Use of Stimulants were significantly higher in the group without a history of
stimulant misuse with Cohen’s d in the large range (Cohen, 1992). Perceptions of
Stimulant Safety, Sharing Stimulants with Other Students, Perceived Knowledge
about Stimulants, past 6-month ADHD total score, and childhood ADHD total, score,
however, were all significantly higher in the group reporting a history of stimulant
misuse, with Cohen’s d effect sizes ranging from small to large (Cohen, 1992). In
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contrast, no significant differences were found for any of the DASS-21 subscales of
depression, anxiety, or stress. Findings should be interpreted with caution, however,
due to significantly different variances across groups in some cases (see table 9).
Additionally, because these analyses were simply exploratory in nature and conducted
post-hoc, no multiple comparison corrections (e.g., Bonferroni) were made (see
Armstrong, 2014).
Factors Predictive of Prescription Stimulant Misuse
For each of the regression models, errors were examined with regard to
assumptions of linearity, normality, and homoscedasticity, as depicted in figures 1-24.
Results should be interpreted cautiously given that assumptions of normality and
homoscedasticity may not have been met, possibly due in part to considerable zeroinflation and hence positive skewness in the dependent variable (see figures 25 and
26). As stated previously, participants holding a current prescription for stimulant
medication were excluded from the regression analyses given the present study’s
definition of stimulant misuse as use of stimulants without a valid prescription.
Prior to conducting regression analyses, preliminary intercorrelational analyses
between all independent and dependent variables were performed. Results, delineated
in table 10, revealed Use of Stimulants for Academic, Cognitive, Physical, and Social
Enhancement was significantly and positively correlated with DASS-21 anxiety scores
(r = 0.195, p < 0.001) and childhood total ADHD score (r = 0.216, p < 0.001). Use of
Stimulants for Partying or Getting High was positively and significantly correlated
with participant sex (r = 0.147, p < 0.04; male sex was associated with greater use),
and with past 6-month total ADHD score (r = 0.105, p < 0.043) childhood total
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ADHD score (r = 0.200, p < 0.001). Neither Use of Stimulants for Academic,
Cognitive, Physical, and Social Enhancement nor Use of Stimulants for Partying or
Getting High was associated with DASS-21 depressive symptoms, DASS-21 stress
symptoms, or GPA. Also of note is that all DASS-21 subscales, depression, anxiety,
and stress, were significantly intercorrelated. ADHD childhood total score was
significantly correlated with ADHD past 6 month total score: r = 0.729, p < 0.001, and
ADHD total scores in both childhood and adulthood were significantly correlated with
all DASS-21 subscales (i.e., depression, anxiety, and stress).
Among participants without a current prescription for stimulant medication,
the first hypothesis, that male sex would be more strongly associated with prescription
stimulant misuse than female sex, was partially supported. Although sex did not
significantly predict Use of Stimulants for Academic, Cognitive, Physical, or Social
Enhancement (see table 11), sex significantly predicted Use of Stimulants for Partying
or Getting High (see table 12), with males being more likely to report such behavior.
Sex, however, only explained 1% in the variance of the dependent variable.
The second hypothesis, that self-reported GPA would be negatively associated
with prescription stimulant misuse, was neither supported for Use of Stimulants for
Use of Stimulants for Partying or Getting High (see table 11) nor for Use of
Stimulants for Academic, Cognitive, Physical, or Social Enhancement (see table 12).
The third hypothesis, that symptoms of depression, anxiety, and stress would
be positively associated with prescription stimulant misuse was partially supported.
Anxiety, but not depression or stress, was significantly and positively associated with
Use of Stimulants for Academic, Cognitive, Physical, or Social Enhancement (see
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table 11). The model explained approximately 4% of the variance in the dependent
variable; hence, the effect size was small. Symptoms of depression, anxiety, and
stress, however, did not significantly predict Use of Stimulants for Partying or Getting
High (see table 12).
The fourth hypothesis, that ADHD symptoms would significantly predict
prescription stimulant misuse while controlling for symptoms of depression, anxiety,
and stress was supported. Both childhood and past 6 months’ symptoms of ADHD
significantly predicted Use of Stimulants for Academic, Cognitive, Physical, or Social
Enhancement. The model explained 9% of the variance in the dependent variable; thus
the effect size was small. Of note, however, is that the relationship between childhood
ADHD symptoms and stimulant misuse was positive whereas for past 6 months’
ADHD symptoms it was negative. With regard to Use of Stimulants for Partying or
Getting High, only childhood symptoms of ADHD emerged as a significant predictor.
The latter model explained 4% of the variance in the dependent variable.
Prevalence of Significant ADHD Symptomatology
Within the entire sample, regardless of prescription status, the percentage of
students reporting current (past 6-months) significant ADHD symptomatology (i.e.,
obtaining a total score of 23) on the DSM Checklist of Symptoms was 10.7% (95%
CI: [7.95%, 13.45%]), and the percentage of students reporting significant childhood
ADHD symptomatology (i.e., obtaining a total score of 25) was 15.2% (95% CI:
[12.01%, 18.39%]). The percentage of participants from the entire sample reporting
significant ADHD symptomatology on the DSM-IV Checklist of Symptoms, both
currently (past 6 months) and in childhood was 8.0% (95% CI: [5.52%, 10.48%]),
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compared with 9.1% of participants endorsing having been diagnosed previously with
ADHD at some point in their lifetime (95% CI: [6.62%, 11.58%]). Of those reporting
having been diagnosed previously with ADHD, 47.83% endorsed the ADHDInattentive subtype, 2.17% endorsed the ADHD-Hyperactive/Impulsive subtype, and
36.96% endorsed the ADHD-Combined subtype, while 13.04% reported not knowing
the subtype with which they had been diagnosed. The correlation between significant
ADHD symptomatology as defined in the present study, and a self-reported, previous
ADHD diagnosis was statistically significant: r = 0.42, p < 0.01. Approximately 38%
of participants with significant ADHD symptoms reported a previous diagnosis of
ADHD, compared with about 6% of participants without significant ADHD
symptoms. Among participants reporting a previous diagnosis of ADHD, only 35%
were classified as having significant ADHD symptoms, based on the present study’s
definition.
Within the group of participants meeting criteria for significant ADHD
symptomatology as defined in the present study, approximately 20% endorsed having
a current prescription for stimulant medication, compared with 4.5% of those not
meeting criteria for significant ADHD symptomatology. Of those participants who
reported a previous ADHD diagnosis, 59.6% endorsed being prescribed stimulant
medication.
Also of interest were potential group differences based on significant ADHD
symptomatology group status. Participants with significant ADHD symptomatology in
both childhood and adulthood, regardless of prescription status, reported greater levels
of depression (t(416) = 2.96, p = 0.006; Cohen’s d = 0.84), anxiety (t(416) = 2.80, p =
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0.009; Cohen’s d = 0.85), and stress (t(416) = 2.45, p = 0.02; Cohen’s d = 0.57)
relative to those without significant ADHD symptoms, as defined in the present study.
Cohen’s d effect sizes were in the medium to large range; however, results should be
interpreted cautiously as the homogeneity of variance assumption may not have been
met. Regarding Use of Stimulants for Academic, Cognitive, Physical, or Social
Enhancement (t(449) = 1.41, p = 0.16) as well as Use of Stimulants for Partying or
Getting High (t(449) = 0.497, p = 0.62), irrespective of prescription status, no
statistically significant group differences were found. Similarly, when those with a
current prescription for stimulant medication were excluded from the analyses,
participants with significant ADHD symptoms did not report significantly greater Use
of Stimulants for Academic, Cognitive, Physical, or Social Enhancement (t(419) = 0.97, p = 0.34) or Use of Stimulants for Partying or Getting High (t(419) = -0.86, p =
0.40) than those without significant ADHD symptoms. Importantly, given that group
differences analyses based on ADHD symptomatology were exploratory in nature and
conducted post hoc, no corrections were made for multiple comparisons (see
Armstrong, 2014).
Additional Post Hoc Analyses
Among participants without a current prescription for stimulant medication,
independent t-tests indicated those reporting a disability did not report significantly
more stimulant misuse for academic, cognitive or other enhancement (t(413) = -1.63,
p = 0.11) or for recreational reasons (t(413) = -1.20, p = 0.24) than participants not
reporting a disability. Variances were not equal across the two groups; therefore,
results should be interpreted with caution. In contrast, significant group differences
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were found for all subscales of the DASS-21; participants with a disability reported
significantly higher depression (t(413) = -2.89, p = 0.005), anxiety (t(413) = -3.63, p =
0.001), and stress (t(413) = -3.48, p = 0.001) than participants without a disability.
The same pattern of results emerged when participants holding a current
prescription for stimulant medication were included in the analyses: Use of Stimulants
for Academic, Cognitive, Physical, or Social Enhancement: (t(449) = -1.71, p = 0.09),
Use of Stimulants for Partying or Getting High: (t(449) = -1.16, p = 0.25), DASS-21
depression (t(449) = -3.62, p = 0.001), DASS-21 anxiety (t(449) = -4.10, p < 0.001),
and DASS-21 stress (t(449) = -4.15, p < 0.001) were not significant across the two
groups.
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Discussion
The present study was the first to examine prevalence rates of prescription
stimulant misuse among college students in Iceland and its relation to student sex,
GPA, psychological symptoms of depression, anxiety, and stress, as well as ADHD
symptoms. Further, the current study sought to identify the prevalence of significant
ADHD symptomatology within this population. Specifically, it was hypothesized that:
1) male sex would be more strongly associated with prescription stimulant misuse than
female sex; 2) self-reported GPA would be negatively associated with prescription
stimulant misuse; 3) symptoms of depression, anxiety, and stress would be positively
associated with prescription stimulant misuse; and 4) ADHD symptomatology would
significantly predict prescription stimulant misuse while controlling for symptoms of
depression, anxiety, and stress. In addition, psychometric analyses were conducted for
the newly translated Icelandic version of the SSQ.
Psychometric Findings
Results revealed the underlying component structure of the Icelandic version
of the SSQ was different from that of the original four factor version (Weyandt et al.,
2009); in the present sample, items were observed to load on seven distinct
components, named: a) Use of Stimulants for Academic, Cognitive, Physical, or
Social Enhancement; b) Use of Stimulants for Partying or Getting High; c) Knowledge
of Other Students’ Use of Stimulants; d) Perceptions of Stimulant Availability; e)
Perceptions of Stimulant Safety; f) Sharing Stimulants with Other Students; and g)
Perceived Knowledge about Stimulants. All components demonstrated acceptable
internal consistency (i.e., > 0.7), except for Sharing Stimulants with Other Students
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(alpha = 0.563), possibly due to suboptimal loadings for two items contributing to this
component. Two plausible explanations regarding these discrepant findings can be
offered. First, the present study used a different method (i.e., Velicer’s MAP and
Horn’s parallel analysis, principal components analysis [O’Connor, 2000]) to
determine the number of components than did Weyandt and colleagues (2009;
principal-axis factor analysis). Second, psychometric non-equivalence of measures
across cultures is a well-known phenomenon in cross-cultural research (Rottig, 2009).
Cultural non-equivalence of measures can lead to difficulty with the interpretation of
findings in different groups (Rottig, 2009); however, even though the current results
suggested another set of underlying components relative to the original version of the
SSQ, qualitatively, the Icelandic components appear to represent constructs similar to
the original four factors, including self-reported stimulant misuse, perceptions of other
students’ use of stimulants, as well as perceptions of stimulant safety. Therefore, it can
be concluded that the SSQ is indeed measuring prescription stimulant misuse and
related beliefs and perceptions among college students in Iceland, similar to the
original, English language version of the instrument.
Prescription Stimulant Misuse Findings: Prevalence and Motivations
The present study was the first to identify prescription stimulant misuse among
college students in Iceland, which is surprising given the high rate of prescriptions
issued each year in Iceland. Results revealed that within the overall sample,
prevalence of lifetime prescription stimulant misuse was 13.2% (95% CI: [10.26%,
16.14%]), among those without a current prescription for stimulant medication, the
overall prevalence of lifetime prescription stimulant misuse was 11.2% (95% CI:
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[8.34%, 14.06%]), while among those holding a prescription it was 42.4% (95% CI:
[25.79%, 59.01%]). Based on descriptive data, participants holding a prescription for
stimulant medication generally reported higher levels of stimulant misuse across all
items of the SSQ. Approximately 8% of participants without a current prescription for
stimulants reported having used these medications to enhance their academic,
cognitive, physical, or social performance while about 10% of participants from this
same group reported having used stimulants to party or to “get high”. These findings
are within the same range (i.e., 3-20%) as those reported in Germany and Switzerland
(e.g., Deline et al., 2014; Dietz et al., 2013; Mache et al., 2012); it is important to note,
however, that prevalence estimates reported in these three studies also encompassed
other substances (e.g., cannabis, amphetamine, caffeine, etc.), which may complicate
comparisons with the present results. On the other hand, Maier et al. (2013)
specifically examined rates of MPH and AMP misuse among university students in
Switzerland, reporting a prevalence rate of 4.5%. Taken together, these findings
indicate that prevalence of misuse of prescription stimulants is comparable, or
possibly higher, among college students in Iceland relative to Germany and
Switzerland.
Compared to the United States, Icelandic prevalence rates are also within the
range of what has been found across studies (i.e., 5.3% - 35%; Weyandt et al., 2013b),
although prevalence estimates from Benson and colleagues’s (2015) meta-analysis
approximate around 17%, which is higher than those of the current study. Based on
these findings, it is plausible that prevalence of stimulant misuse behavior is higher in
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Iceland than in Europe, but lower than in the United States. More research is needed to
further examine this hypothesis.
In terms of motivations for misusing stimulant medication, the most commonly
endorsed reason, regardless of prescription status, was to enhance academic
performance (i.e., “to perform better in schoolwork” [53.7% among participants with a
history of stimulant misuse]). This is in accordance with the literature from both the
United States (e.g., Benson et al., 2015; Weyandt et al., 2013b), as well as Europe
(Deline et al., 2014; Dietz et al., 2013; Mache et al., 2012; Maier et al. 2013),
reporting desired improvement of academic performance as the main reason for
stimulant misuse. These findings lend support to the notion that students may use
prescription stimulants as a support strategy and further suggests these students
perceive themselves as struggling academically. Other commonly endorsed reasons
included cognitive and physical enhancement (e.g., “to perform better on tests”
[43.3% among participants with a history of stimulant misuse] or “to feel more
energetic” [44.8% among participants with a history of stimulant misuse]) as well as
recreational motivations (e.g., “to get high” [28.4% among participants with a history
of stimulant misuse]).
As a group, participants with and without a valid prescription generally felt
neutral or disagreed that misuse of prescription stimulants is a problem on campus,
and that stimulants are easily accessible. These results differ from findings reported by
Weyandt et al. (2009), wherein 50% of participants agreed or strongly agreed that
stimulants are easily obtainable. These findings are also interesting given that
approximately 13% of the entire sample reported having engaged in one or more
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stimulant misuse behaviors at least rarely. Therefore, it appears that although stimulant
misuse is indeed occurring among college students in Iceland, students may not
necessarily be aware of it and/or may not perceive this behavior as particularly
problematic.
Based on descriptive data, a higher percentage (i.e., 17.6% – 32.4%) of
Icelandic participants holding a prescription for stimulants agreed or strongly agreed
that occasional and/or daily stimulant misuse is harmless compared to those without a
prescription (i.e., 1.9% - 7.4%). Students with a prescription also reported feeling
more knowledgeable about stimulant medications and their side effects than students
without a prescription, as would be expected. A large majority of participants with and
without a prescription reported knowing about peers who engage in stimulant misuse
behavior for academic, cognitive, or recreational reasons. Finally, more than half of
the students holding a prescription reported hiding their medication to prevent their
peers from taking them, similar to results reported by Weyandt et al. (2009).
Findings indicated a significant, positive association between use of stimulants
for academic, cognitive, and other enhancement reasons and use of stimulants for
recreational reasons. Stimulant use for both reasons was also significantly correlated
with sharing stimulants with peers (i.e., diversion) and increased perceptions of
stimulant safety, as well as greater perceived knowledge about stimulants.
Group Differences based on Stimulant Misuse History
Group differences in psychological functioning based on stimulant misuse
history status among students without a current prescription were also of interest.
Findings suggested past 6-month total number of ADHD symptoms as well as
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childhood total symptoms of ADHD were significantly higher in the group reporting a
history of stimulant misuse than among those without such history. In contrast,
depression, anxiety, and stress were not statistically different across the two groups.
Overall, the results support the hypothesis that Icelandic college students who misuse
stimulants are more likely to demonstrate ADHD symptomatology relative to nonusers. Future studies are needed to examine this association in greater detail.
In addition, participants reporting a history of stimulant misuse scored
significantly higher than those without such history with regard to perceptions of
stimulant safety, sharing stimulants with peers, and perceived knowledge about
stimulants. These results have critical implications for prevention and intervention
targeting stimulant misuse behavior, and highlight the importance of educating college
students about the risks associated with misuse of these drugs. Given that many
students appear to acquire stimulants from peers with a valid prescription (see
Weyandt et al., 2013b) it behooves physicians who prescribe stimulant medication to
emphasize the numerous risks associated with stimulant medication diversion and
misuse with their patients.
Factors Predictive of Prescription Stimulant Misuse
The present study identified several variables that are predictive of stimulant
misuse behavior among college students in Iceland. Preliminary correlational analyses
revealed Use of Stimulants for Academic, Cognitive, Physical, and Social
Enhancement was significantly and positively correlated with anxiety and ADHD
symptoms in childhood. Alternatively, Use of Stimulants for Partying or Getting High
was positively and significantly correlated with participant sex, wherein being male
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was associated with greater use, and with childhood and past 6-month symptoms of
ADHD. No significant correlations between depressive symptoms, stress, or GPA and
stimulant misuse behavior were observed.
The first hypothesis, that male sex would be more strongly associated with
stimulant misuse than female sex, was supported, although the effect size was small.
Participants who were male were significantly more likely to endorse having engaged
in prescription stimulant misuse for partying or “getting high”, but not for academic,
cognitive, or other enhancement reasons. The current results echo findings reported by
Weyandt and colleages (2013b) as well as Benson et al. (2015) regarding greater
misuse among males relative to females, although neither of those studies specified the
primary motives behind this behavior among males, compared to females.
Contrary to expectations, the second hypothesis, that self-reported GPA would
be negatively associated with prescription stimulant misuse, was not supported. These
findings can be contrasted with those reported by Benson et al. (2015) wherein a lower
GPA was associated with greater odds of engaging in stimulant misuse. It is unclear
why this relationship did not emerge in the current study, but one possible explanation
is that grading conventions differ across the two countries and GPA may therefore
differentially associate with other outcomes.
The third hypothesis, that symptoms of depression, anxiety, and stress would
be positively associated with prescription stimulant misuse was partially supported.
Anxiety, but not depression or stress, was significantly and positively associated with
use of stimulants for academic, cognitive, and other enhancement reasons (small effect
size); however no significant associations were found for use of stimulants for
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recreational reasons. This provides further support to the hypothesis that students who
struggle academically may use stimulant medications to help cope with educational
demands.
The fourth hypothesis, that ADHD symptoms would significantly predict
prescription stimulant misuse while controlling for symptoms of depression, anxiety,
and stress was supported; both childhood and past 6-month total symptoms of ADHD
significantly predicted stimulant use for academic, cognitive, and other enhancement
reasons, with a small effect size. Interestingly, however, the relationship between
childhood ADHD symptoms and stimulant misuse was positive while for past 6month ADHD symptoms it was negative, indicating greater past 6 month ADHD
symptomatology is associated with lower use of stimulants for academic, cognitive,
and other enhancement reasons. In contrast, correlational analyses suggested ADHD
symptoms in both childhood and adulthood were positively associated with stimulant
misuse behavior. It is unclear why the relationship between ADHD symptoms and
stimulant misuse behavior was different for childhood compared to adulthood when
both constructs were included in the same regression model; one plausible explanation
is the relatively high correlation (i.e., r = 0.74) between ADHD symptoms in
adulthood and childhood, possibly suggesting multicollinearity (see Kraha, Turner,
Nimon, Zientek, & Henson, 2012). With regard to stimulant use for recreational
reasons, only childhood symptoms of ADHD emerged as a significant, positive
predictor. Collectively, the findings support the notion that a history of ADHD
symptoms increases the likelihood of misuse of stimulant medication. Further research
is needed to examine this relationship in greater detail.
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The present findings have the potential to inform public health policies
concerning college student mental health and well-being as well as stimulant
medication management in Iceland. Greater access to psychological and academic
support services for students who struggle due to ADHD, ADHD symptomatology, or
other psychological difficulties may be beneficial and provide students with safer and
more appropriate strategies for coping with the challenges of the college environment.
Additionally, psychoeducational interventions regarding the risks of psychostimulant
medication diversion and misuse are clearly warranted, especially within the college
population.
ADHD Symptomatology Findings
The prevalence of persistent (i.e., occurring both in childhood and adulthood),
significant ADHD symptomatology within the sample as a whole was 8.0% (95% CI:
[5.52%, 10.48%]) while 9.1% of participants reported having been previously
diagnosed with ADHD. The correlation (r = 0.42, p < 0.01), or agreement, between
significant ADHD symptomatology and having a previous ADHD diagnosis was
statistically significant. Moreover, 38% of participants meeting study criteria for
significant ADHD symptoms reported a previous diagnosis of ADHD, compared with
about 6% of participants without significant ADHD symptoms. Conversely, only 35%
of participants reporting a previous diagnosis of ADHD were classified as having
significant ADHD symptoms.
Therefore, results indicate more than 60% of participants identified as having
significant ADHD symptoms had not been formally diagnosed with ADHD. This
suggests the present definition of “significant ADHD symptoms” may have lacked
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specificity, leading to a number of false positives, and/or many of the participants
identified truly have ADHD that has not been diagnosed. It is important to note,
however, that “significant ADHD symptoms”, as defined in the current study, should
not be conceptualized as a formal ADHD diagnosis given that this categorization is
solely based on self-reported rating scale data. Instead, these numbers provide a rough
estimate of the prevalence of problems associated with attention and/or
hyperactivity/impulsivity that in some cases may warrant clinical attention.
These results are inconsistent with those reported by Gudjonsson and
colleagues (2009) who also investigated the prevalence of ADHD among college
students in Iceland. Gudjonsson et al (2009) found only 1 out of 369 participants met
somewhat more stringent criteria for the disorder, while the prevalence of
subthreshold ADHD, or ADHD in partial remission, was 10%, which is more
comparable to the current findings. Further, in the Gudjonsson et al. (2009) study, the
percentage of students reporting a prior diagnosis of ADHD was 1%, which is also
lower than the current results suggested. Although both studies relied on convenience
samples, a particular strength of the present study was the recruitment of participants
from the four largest universities in Iceland, whereas Gudjonsson and colleagues
(2009) recruited participants from one university only. Therefore, it can be argued that
the current sample was somewhat more representative of the larger Icelandic college
student population.
Results suggested as a group, Icelandic college students with elevated ADHD
symptoms experience greater psychological distress relative to those with fewer
ADHD symptoms, as these participants reported significantly higher levels of
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depression, anxiety, and stress, with effect sizes in the medium to large range. In
contrast, no statistically significant differences in stimulant misuse behavior based on
ADHD symptomatology status were found.
Regarding treatment, approximately 20% of participants with significant
ADHD symptomatology, as defined in the present study, reported holding a current
prescription for stimulant medication, compared with 4.5% of those not meeting
criteria for significant ADHD symptomatology. Therefore, a large majority of
participants with significant ADHD symptoms, as defined in the current study, were
not prescribed medication to address these symptoms. Conversely, approximately 60%
of participants reporting a previous ADHD diagnosis endorsed having been prescribed
stimulant medication.
The present findings suggest that a significant subgroup of Icelandic college
students demonstrate elevated ADHD symptomatology. Whether or not these students
would meet diagnostic criteria for the disorder is unclear; however, the current results
indicate these students are at greater risk for symptoms of depression, anxiety, and
stress, relative to those without significant ADHD symptoms. These findings add to a
growing body of literature that attests to the relationship between ADHD
symptomatology and a variety of psychosocial difficulties among college students
(e.g., Anastopoulos et al., in press; Weyandt & DuPaul, 2013). The findings also
highlight the importance of providing these students with effective treatment and
support in the college environment. Research regarding treatment of ADHD in college
students is scarce and preliminary; however, findings reported by Anastopoulos and
King (2015) concerning a treatment program for college students with ADHD,
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consisting of cognitive behavior therapy (CBT) and individual mentoring, were
promising and included greater ADHD knowledge, enhanced organizational skills, and
increased adaptive thinking. Similarly, LaCount, Hartung, Shelton, Clapp, and Clapp
(2015) reported a decrease in self-reported ADHD symptoms and academic
impairment as a result of individual and group CBT sessions targeting organizational
and time-management skills among college students with elevated ADHD symptoms.
Finally, Fleming, McMahon, Moran, Peterson, and Dreessen (2015) conducted a
randomized controlled pilot trial offering group sessions of dialectical behavior
therapy (DBT) to college students with ADHD. DBT training was associated with
greater improvement in ADHD symptoms and quality of life than the control
condition. Increased availability and access to similar support services for college
students in Iceland, especially those who struggle with ADHD symptoms and other
psychosocial difficulties, may be warranted.
Additional Post Hoc Findings
Group differences based on disability status were also explored. Within the
group without a current prescription for stimulant medication, results revealed
participants endorsing having some form of a disability were not significantly more or
less likely than participants without disabilities to disclose a history of stimulant
misuse. These findings are similar to those reported by Janusis and Weyandt (2010)
who found that this same pattern of results emerged when students holding a current
prescription for stimulant medication were included in the analyses. The current
findings should be interpreted with caution, however, as results suggested significant
heterogeneity of variance across groups.
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In contrast, as a group, students reporting a disability endorsed significantly
higher levels of depression, anxiety, and stress than students without a disability.
Hence, it is important that college students with disabilities be offered and encouraged
to access academic and psychosocial support services.

Limitations and Future Directions
Several limitations of the present study should be discussed. First, the current
study employed a convenience sample, which may limit the generalizability of the
findings. As noted previously, although the current sample included students from the
four largest universities in Iceland, the extent to which it represents the larger college
student population in Iceland is unclear. Second, the sample was disproportionately
female, which also may serve to reduce the generalizability of the findings. Given the
current results that males were more likely than females to engage in stimulant misuse
for recreational reasons, it is possible that the present study underestimated the
prevalence of this behavior among male college students. Third, assumptions of
normality and homoscedasticity for t-test and regression analyses may not have been
met, emphasizing the need for cautious interpretation of the findings. Fourth, the study
was correlational in design and, as such, does not permit any causal inferences
regarding the relationship between the variables of interest. Fifth, the current study did
not address other substance use behavior (e.g., use of alcohol, tobacco, marijuana,
etc.), which may be an important correlate of stimulant misuse behavior (Benson et al.,
2015). Finally, the age range of participants in the current study was much wider (i.e.,
19-57 years) than that of participants in similar studies conducted in the United States
(i.e., typically 18-25 years).
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Future studies regarding prescription stimulant misuse using representative
samples of college students in Iceland are needed. Ideally, such studies would be
longitudinal and prospective in nature, include a rigorous assessment of ADHD and
related psychosocial issues, and address the potential relationship between prescription
stimulant misuse and other substance use behaviors. Additionally, although the current
study was not neurobiologically focused, future research is needed to elucidate the
pathophysiology of ADHD symptomatology and comorbid conditions (e.g., anxiety
and depression) and the effects of psychostimulants on these biological mechanisms.

Conclusion
The current study was the first to investigate misuse of prescription stimulant
medication among college students in Iceland. Results revealed a prevalence rate of
approximately 11% among participants without a prescription for stimulants, 42%
among participants with a prescription, and 13% within the overall sample (among
participants with and without a current prescription). Based on these findings, the
prevalence of this behavior appears to be higher in Iceland than in other European
countries, but lower than in the United States. Participants reported the primary and
secondary reasons for misusing stimulants included academic, cognitive, physical, and
social enhancement as well as partying and/or getting high, similar to results from
studies conducted with college students in the United States and in Europe.
Preliminary evidence from the current study indicates risk factors for
prescription stimulant misuse among college students in Iceland include being male,
experiencing symptoms of anxiety, and having a history of ADHD symptoms. The
results of the current study also revealed that approximately 8% of Icelandic college
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students sampled reported persistent, elevated ADHD symptomatology, and students
with a history of prescription stimulant misuse had significantly higher ADHD
symptoms than those without such history.
Interestingly, correlational analyses suggested a positive relationship between
ADHD symptoms and stimulant misuse, both with regard to childhood and adulthood
ADHD symptoms. Multiple regression analyses, however, presented a more
complicated picture, wherein childhood symptoms of ADHD were positively
associated with stimulant misuse, and current ADHD symptoms negatively predicted
stimulant misuse. Cautious interpretation of these results is warranted, however, given
the study’s limitations.
The present findings have important implications for public health policy in
Iceland, particularly as it relates to the college population. Educating college students
about the risks of ADHD prescription stimulant medication misuse and diversion is
clearly warranted. Given that many college students who misuse prescription
stimulants appear to do so to “self-medicate”, or to cope with the various challenges
they face, it is critically important to provide students with safer strategies to manage
academic demands in order to promote health and well-being.
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Table 1. Participant demographics
Category
Sex

N

Percent

Female
Male
Race/Ethnicity
White
Non-White
Other
ADHD Diagnosis
Disability

424
97

81.4
18.6

517
3
1
47
69

99.2
0.6
0.2
9.0
13.2
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Table 2. Initial, 8-component PCA with Varimax rotation
Item
1. I have used prescription stimulants
for non-medical purposes.
2. I have used prescription stimulants
at parties.
3. I have used prescription stimulants
with alcohol.
4. I have snorted prescription
stimulants.
5. I have injected prescription
stimulants.
6. I have smoked prescription
stimulants.
7. I have taken prescription stimulants
to focus better in class.
8. I have taken prescription stimulants
to perform better on tests.
9. I have taken prescription stimulants
to help me socialize better.
10. I have taken prescription
stimulants to help me lose weight.
11. I have taken prescription
stimulants to perform better in my
school work.
12. I have taken prescription
stimulants to feel more energetic.
13. I have taken prescription
stimulants to feel better about myself.
14. I have taken prescription
stimulants to “get high”.
15. I have been offered prescription
stimulants by other students.
16. I have tried someone else’s
prescription stimulant medication.
17. I have purchased prescription
stimulants from other students.
18. I have sold prescription stimulant
medication to other students.
19. I have given prescription
stimulant medication to other
students.
20. I have been pressured into letting
someone else have my prescription
stimulant medication.
21. Prescription stimulants are easy to
get on this campus.
22. Prescription stimulants are as easy
to get as alcohol.

Component
1
2
.424

.728

.194

.892

.250

.858

.066

.664

N/A

N/A

.072

.338

.851

.199

.889

.133

.465

.388

.534

.347

.874

.180

.775

.307

.706

.234

.109

.791

.198

.396

.373

.546

.155

3
.111
.156
.125
.206
N/A
.099
.073
.041
.126
.030
.043
.030

4

5

6

7

8

.007
.042
.034
.021

.114

.102

.090

.141

.083

.079

.085

.026

.076

.080

.100

.023

.104

.006

.020

0.55

N/A

N/A
.032

N/A
.109

N/A
.015

N/A

.115

.092

.019

.119

.003

.053

.054
.140

.562
.153

.018
.008

.120

.151

.068

.326

.130

.032
.069
.035

.198

.014

.061

.107

.020

.256

.049
.020
.028
.091
.045

.108

.069

.762

.057

.045
.003
.032
.027
.058

.009
.017

.194
.382
.076
.144

.039

.273

.186
.001

.001
.093
.305
.097
.109
.082

.020

.139

.757

.045

.224
.156
.021
.102
.176

.535

.315

.053

.051

.114

.076

.081

.406

.449

.007

.090

.110

.445

.033
.004

.100

.846

.089
.017

.052
.011

.143
.011

.180
.113

.055

.066

.012

69

.136
.144
.047

.840

.372

.550
.027
.083

.053

.303

23. Prescription stimulants are as easy
to get as marijuana.
24. Using prescription stimulants
occasionally is harmless.
25. Using prescription stimulants
daily is harmless.
26. Prescription stimulant use on
campus is a problem.
27. Prescription stimulants are safer
than marijuana.
28. Prescription stimulants are safer
than alcohol.
29. I feel I am knowledgeable about
prescription stimulants.
30. I feel I am knowledgeable about
the side effects of prescription
stimulants.
31. I know students who use
prescription stimulants at parties.
32. I know students who use
prescription stimulants with alcohol.
33. I know students who use
prescription stimulants with other
drugs.
34. I know students who use
prescription stimulants while
studying.
35. I know students who use
prescription stimulants during finals
week/tests.
36. I know students who snort
prescription stimulants.
37. I know students who inject
prescription stimulants.
38. I know students who smoke
prescription stimulants.
39. I hide my prescription stimulant
medication so that no one will take it.

.040

.077

.152

.232
.054
.166

.073
.056

.821

.138

.006

.730

.076
.294

.044

.058

.114

.068

.067

.055

.128
.118
.070

.114
.092
.096

.081
.172
.197

.024

.037
.023

.746

.056
.021
.060

.500

.043

.001

.082

.064

.742

.125

.038
.103

.105

.814
.072

.101

.176
.065
.018

.040

.944

.110

.088

.031

.014

.139
.026
.026
.016

.838

.273

.737

.085

.010

.048

.075

.113

.216

.185

.682

.240

.010

.016

.078

.302

.215

.103
.150

.011

.071

.030
.009

.028
.027
.017

.120
.009
.011
.343

.659
.661

.167
.021

.442

.100

.138

70

.577

.246
.062
.198
.073
.058

.063

.941
.112
.096

.211

.075
.083
.074

.845

.006
.102
.107

.014
.224
.056

.072

.025
.188

.259

.051
.024
.004
.083
.229

.019
.021

.291
.088
.187
.405
.287

Table 3. Final, 7 component PCA with Varimax rotation
Item

Component
1
2

1. I have used prescription stimulants for nonmedical purposes.
2. I have used prescription stimulants at parties.
3. I have used prescription stimulants with alcohol.
4. I have snorted prescription stimulants.
6. I have smoked prescription stimulants.
7. I have taken prescription stimulants to focus
better in class.
8. I have taken prescription stimulants to perform
better on tests.
9. I have taken prescription stimulants to help me
socialize better.
10. I have taken prescription stimulants to help me
lose weight.
11. I have taken prescription stimulants to perform
better in my school work.
12. I have taken prescription stimulants to feel
more energetic.
13. I have taken prescription stimulants to feel
better about myself.
14. I have taken prescription stimulants to “get
high”.
15. I have been offered prescription stimulants by
other students.
16. I have tried someone else’s prescription
stimulant medication.
17. I have purchased prescription stimulants from
other students.
18. I have sold prescription stimulant medication to
other students.
21. Prescription stimulants are easy to get on this
campus.
22. Prescription stimulants are as easy to get as
alcohol.
23. Prescription stimulants are as easy to get as
marijuana.
24. Using prescription stimulants occasionally is
harmless.
25. Using prescription stimulants daily is harmless.
26. Prescription stimulant use on campus is a
problem.
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3

.431 .662 .126
.203 .874 .154
.256 .840 .124
.081 .661 .204
.121 .448 .088
.856 .161 .094
.883 .082 .072
.492 .406 .102
.562 .405 .040
.876 .131 .063
.827 .295 .044
.753 .263 .003
.136 .816 .083
.114 .369 .287
.343 .511 .089
.115 .157 .062
.246 .037 .048
.008 .080 .148
.013 .030 .048
.041 .081 .062
.131 .162 .078
.102 .069 .064
.088 .112 .275

4
.025
.056
.048
.030

5

6

7

.191 .162 .161
.113 .106 .105
.106 .110 .119

.123 .019 .031
.102 .126 .247 .128
.017 .157 .101 .053
.049 .179 .041 .108
.031 .001 .500 .037
.079 .167 .201 .045
.010 .167 .165 .108
.018 .044 .154 .052
.053 .111 .267 .068
.115 .033 .073 .026
.144 .051 .320 .029
.073 .046 .373 .006
.062 .040 .809 .040
.003 .105 .781 .017
.822 .120 .147 .018
.848 .020 .020 .036
.815 .138 .079
.021 .790 .052
.045 .737 .042
.536 .006 .112

.036
.040
.002
.105

27. Prescription stimulants are safer than
marijuana.
28. Prescription stimulants are safer than alcohol.

.062 .079 .104 .083 .687 .074 .112
.112 .062 .051 .108 .794 .095 .030
29. I feel I am knowledgeable about prescription
stimulants.
.064 .044 .098 .096 .077 .032 .932
30. I feel I am knowledgeable about the side effects
of prescription stimulants.
.108 .075 .101 .088 .048 .007 .927
31. I know students who use prescription
stimulants at parties.
.077 .166 .843 .078 .060 .132 .124
32. I know students who use prescription
stimulants with alcohol.
.077 .190 .836 .067 .050 .146 .108
33. I know students who use prescription
stimulants with other drugs.
.002 .299 .726 .090 .030 .084 .050
34. I know students who use prescription
stimulants while studying.
.178 .105 .696 .203 .106 .129 .174
35. I know students who use prescription
stimulants during finals week/tests.
.189 .025 .680 .210 .092 .058 .154
36. I know students who snort prescription
stimulants.
.119 .176 .650 .071 .047 .028 .010
37. I know students who inject prescription
stimulants.
.002 .122 .434 .158 .053 .061 .069
38. I know students who smoke prescription
stimulants.
.045 .111 .563 .129 .114 .116 .183

Notes. The columns in which item component loadings are bolded represent the
component to which each item belongs. In cases where more than 1 component
loading is bolded, the underlined loading represents the component to which the item
was ultimately added.
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Table 4. SSQ Components, eigenvalues, and % of variance explained
SSQ Component
SSQ Component 1 Use of Stimulants for Academic, Cognitive,
Physical, or Social Enhancement
SSQ Component 2 Use of Stimulants for Partying or Getting High
SSQ Component 3 Knowledge of Other Students’ Use of Stimulants
SSQ Component 4 Perceptions of Stimulant Availability
SSQ Component 5 Perceptions of Stimulant Safety
SSQ Component 6 Sharing Stimulants with Other Students
SSQ Component 7 Perceived Knowledge about Stimulants
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Eigenvalues % of
Variance

Cumulative
%

4.61

13.56%

13.56%

4.36

12.81%

26.37%

4.20

12.36%

38.73%

2.61

7.67%

46.40%

2.56

7.54%

53.93%

1.97

5.79%

59.73%

1.93

5.67%

65.40%

Table 5. Correlation matrix for the 7 components of the Icelandic translation of the
SSQ among participants without a current prescription
SSQ Component
SSQ Component 1 Use of Stimulants for Academic,
Cognitive, Physical, or Social
Enhancement
SSQ Component 2 Use of Stimulants for Partying or
Getting High
SSQ Component 3 Knowledge of Other Students’ Use of
Stimulants
SSQ Component 4 Perceptions of Stimulant Availability
SSQ Component 5 Perceptions of Stimulant Safety
SSQ Component 6 Sharing Stimulants with Other Students
SSQ Component 7 Perceived Knowledge about Stimulants

C1

C2

C3

1 .554**

.231**

.032 .188** .463** .155**

1

.359**

.081 .179** .512** .148**

.231** .359**

1

.554**

.032

.081

.188** .179**
.463** .512**
.155** .148**

.305

**

C4

.305**

C5

.009

C6

C7

.381** .226**

1 .121** .153** .151**

.009 .121**

1 .173** -.038

.153** .173**
1 .109*
.381**
**
-.038 .109*
1
** .151
.226

Notes. * = Correlation is significant at the 0.05 level. ** = Correlation is significant at
the 0.01 level
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Table 6. Prevalence of stimulant misuse behaviors
Item

1. I have used prescription stimulants for
non-medical purposes.
2. I have used prescription stimulants at
parties.
3. I have used prescription stimulants with
alcohol.
4. I have snorted prescription stimulants.
5. I have injected prescription stimulants.
6. I have smoked prescription stimulants.
7. I have taken prescription stimulants to
focus better in class.
8. I have taken prescription stimulants to
perform better on tests.
9. I have taken prescription stimulants to
help me socialize better.
10. I have taken prescription stimulants to
help me lose weight.
11. I have taken prescription stimulants to
perform better in my school work.
12. I have taken prescription stimulants to
feel more energetic.
13. I have taken prescription stimulants to
feel better about myself.
14. I have taken prescription stimulants to
“get high”.
15. I have been offered prescription
stimulants by other students.
16. I have tried someone else’s prescription
stimulant medication.
17. I have purchased prescription stimulants
from other students.
18. I have sold prescription stimulant
medication to other students.
19. I have given prescription stimulant
medication to other students.
20. I have been pressured into letting
someone else have my prescription
stimulant medication.

% endorsing item/behavior as having occurred
at least “rarely”
Total
n=487 without
n=34 with
N=521
prescription
prescription
9.3%
9.0%
14.7%
6.2%

6.1%

8.8%

6.5%

5.9%

14.7%

3.5%
0.0%
0.8%
4.4%

3.3%
0.0%
0.6%
3.2%

5.9%
0.0%
2.9%
23.5%

5.6%

4.0%

29.4%

3.1%

2.7%

9.1%

2.1%

1.7%

8.2%

7.3%

5.7%

32.4%

6.0%

4.9%

23.5%

2.3%

1.9%

8.8%

4.0%

4.2%

2.9%

7.7%

6.7%

17.6%

2.3%

2.1%

5.9%

1.2%

1.1%

2.9%

0.4%

0.2%

2.9%

1.9%

1.2%

11.8%

2.5%

1.3%

20.6%
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Table 7. Percentage of students who responded “agree” or “strongly agree” to
statements concerning prescription stimulant use and availability
Item

21. Prescription stimulants are easy to get
on this campus.
22. Prescription stimulants are as easy to
get as alcohol.
23. Prescription stimulants are as easy to
get as marijuana.
24. Using prescription stimulants
occasionally is harmless.
25. Using prescription stimulants daily is
harmless.
26. Prescription stimulant use on campus
is a problem.
27. Prescription stimulants are safer than
marijuana.
28. Prescription stimulants are safer than
alcohol.
29. I feel I am knowledgeable about
prescription stimulants.
30. I feel I am knowledgeable about the
side effects of prescription stimulants.

% endorsing either “agree” or strongly agree”
Overall
n=487 without
n=34 with
N=521
prescription
prescription
11.2%
11.0%
11.8%
7.8%

7.2%

11.8%

18.6%

18.7%

20.6%

7.9%

7.4%

32.4%

2.0%

1.9%

17.6%

13.8%

14.5%

8.8%

4.6%

3.9%

14.7%

4.5%

3.4%

14.7%

45.0%

42.7%

76.5%

44.0%

41.3%

85.3%
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Table 8. Percentage of participants who responded “YES” to statements concerning
prescription stimulant misuse
Item

31. I know about students who use
prescription stimulants at parties.
32. I know about students who use
prescription stimulants with alcohol.
33. I know about students who use
prescription stimulants with other drugs.
34. I know about students who use
prescription stimulants while studying.
35. I know about students who use
prescription stimulants during finals
week/tests.
36. I know about students who snort
prescription stimulants.
37. I know about students who inject
prescription stimulants.
38. I know about students who smoke
prescription stimulants.
39. I hide my prescription stimulant
medication so that no one will take it.

% agreeing to statement
Overall
n=487 without
N=521
prescription
82.1%
82.1%

n=34 with
prescription
85.3%

83.5%

83.4%

85.3%

91.0%

91.4%

88.2%

78.5%

78.9%

76.5%

76.4%

76.7%

76.5%

93.5%

93.3%

94.1%

99.2%

99.2%

100.0%

96.5%

96.6%

93.9%

N/A

N/A

55.9%
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Table 9. Descriptive statistics and independent t-test analyses for SSQ, DASS-21, and
DSM-IV Checklist scores for participants without a current prescription by stimulant
misuse history status
t (346)

Cohen’s
d

N/A

N/A

3.41
(3.29)

N/A

N/A

7.23
(1.61)

5.61
(2.22)

4.41**

0.96

20

10.29
(3.00)

10.54
(3.09)

-0.48

-0.08

4

20

-0.62

8

8.31
(2.81)
0.82
(1.64)

-3.57**

0

6.61
(2.75)
0.06
(0.28)

-2.92**

-1.26

2

10

5.98
(2.50)

7.18
(2.57)

-2.76**

-0.48

0

46

Variable

Min Max

21

n=309 no
history of
stimulant
misuse
M (SD)
N/A

n=39
history of
stimulant
misuse
M (SD)
4.23
(5.72)

SSQ – Component 1
Use of Stimulants for Academic,
Cognitive, Physical, or Social
Enhancement
SSQ – Component 2
Use of Stimulants for Partying or
Getting High
ΨSSQ – Component 3
Knowledge of Other Students’
Use of Stimulants
SSQ – Component 4
Perceptions of Stimulant
Availability
SSQ – Component 5
Perceptions of Stimulant Safety
ΨSSQ – Component 6
Sharing Stimulants with Other
Students
SSQ – Component 7
Perceived Knowledge about
Stimulants
ΨADHD Total – past 6 months

0

0

17

N/A

0

8

4

9.37
12.46
-1.93*
-0.38
(7.89)
(9.58)
ΨADHD Total – childhood
0
54
9.41
16.18
-2.87** -0.64
(10.06)
(14.27)
DASS-Depression
0
21
3.65
3.95
-0.41
-0.07
(4.33)
(4.30)
DASS-Anxiety
0
15
2.06
2.74
-1.27
-0.22
(3.04)
(3.20)
DASS-Stress
0
20
4.45
4.59
-0.22
-0.03
(4.10)
(3.84)
Notes. Ψ = variances were significantly different across groups, results should be interpreted
with caution. * = significant at the 0.05 level. ** = significant at the 0.01 level.
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Table 10. SSQ Use of Stimulants for Academic, Cognitive, Physical, and Social
Enhancement, and Use of Stimulants for Partying or Getting High Pearson
correlations with DASS subscales (depression, anxiety, and stress), ADHD total
scores in childhood and adulthood, participant sex, and self-reported GPA
Variable
A: DASS-21 depression

A

B

C

**

**

1 .604

B: DASS-21 anxiety

.604**

C: DASS21 stress

.707** .707**

D: GPA
E: Participant Sex

.707

1 .707**
1

-.036 -.042 -.025
-.016 -.054
.106*

F: DSM-IV Checklist:
ADHD total score past 6
.411** .405** .436**
months
G: DSM-IV Checklist:
.179** .220** .202**
ADHD total score childhood
H: SSQ Use of Stimulants
for Academic, Cognitive,
.058 .195** .087
Physical, or Social
Enhancement
I: SSQ Use of Stimulants for
-.036 .064 .028
Partying or Getting High

D
.036
.042
.025
1
.020
.042

E
-.016 .411

F

G

**

**

I

.058 -.036

-.054 .405** .220** .195**

.064

.436** .202** .087 .028
.106*
-.020 -.042 -.010 -.010 -.020
1

.060 .190**

.023 .147**

.060

1 .729**

.089 .105*

.190** .729**
.010
.010

.179

H

.023

1 .216** .200**

.089 .216**

1 .657**

.147** .105* .200** .657**
.020

1

Notes. * = Correlation is significant at the 0.05 level. ** = Correlation is significant at
the 0.01 level.
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Table 11. Regression analyses with Use of Stimulants for Academic, Cognitive,
Physical, or Social Enhancement component of SSQ as the dependent variable
Independent variable(s) t
Model 1

Sex

β

p

0.97

0.33

F

df

p

adj. R2

0.94 1, 468

Model summary
0.33
0.00

0.07 1, 364

Model summary
0.78
0.00

0.05

Model 2

GPA -0.28

0.78 -0.01

Model 3
Model summary
6.29 3, 417 <0.001
0.04
Depression -0.81
0.42 -0.06
Anxiety 3.84 <0.001 0.26
Stress -0.54
0.59 -0.04
Model 4
Model summary
8.08 5, 378 <0.001
0.09
ADHD past 6 months -2.91
0.004 -0.24
ADHD childhood 4.65 <0.001 0.34
Depression -0.51
0.61 -0.04
Anxiety 3.69 <0.001 0.26
Stress -0.51
0.61 -0.04
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Table 12. Regression analyses with Use of Stimulants for Partying or Getting High
component of SSQ as the dependent variable
Independent variable(s) t
Model 1

Sex

β

p

2.17

0.03

F

df

p

adj. R2

4.71 1, 468

Model summary
0.03
0.01

0.32 1, 457

Model summary
0.57
0.00

1.78 3, 419

Model summary
0.15
0.01

0.10

Model 2

GPA -0.56

0.57

-0.03

Model 3

Depression -1.56
Anxiety 1.61
Stress 0.70

0.12 -0.112
0.11 0.110
0.49 0.056

Model 4
3.81
ADHD past 6 months -0.96 0.34
ADHD childhood 3.21 0.001
Depression -1.77 0.08
Anxiety 1.16 0.25
Stress 0.46 0.65

-0.08
0.24
-0.13
0.09
0.04
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Model summary
5,379 0.002
0.04

Figure 1. Regression model with Sex as the IV and Use of Stimulants for Academic,
Cognitive, Physical, or Social Enhancement as the DV: Assessment of independence
of errors assumption

Figure 2. Regression model with Sex as the IV and Use of Stimulants for Academic,
Cognitive, Physical, or Social Enhancement as the DV: Assessment of independence of
errors assumption
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Figure 3. Regression model with Sex as the IV and Use of Stimulants for Academic,
Cognitive, Physical, or Social Enhancement as the DV: Assessment of normal
distribution assumption

Figure 4. Regression model with Sex as the IV and Use of Stimulants for Partying or
Getting High as the DV: Assessment of independence of errors assumption

83

Figure 5. Regression model with Sex as the IV and Use of Stimulants for Partying
or Getting High as the DV: Assessment of homogeneity of variance and linearity
assumption

Figure 6. Regression model with Sex as the IV and Use of Stimulants for
Partying or Getting High as the DV: Assessment of normal distribution
assumption
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Figure 7. Regression model with GPA as the IV and Use of Stimulants for
Academic, Cognitive, Physical, or Social Enhancement as the DV: Assessment of
independence of errors assumption

Figure 8. Regression model with GPA as the IV and Use of Stimulants for
Academic, Cognitive, Physical, or Social Enhancement as the DV: Assessment of
homogeneity of variance and linearity assumption
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Figure 9. Regression model with GPA as the IV and Use of Stimulants for Academic,
Cognitive, Physical, or Social Enhancement as the DV: Assessment of normal distribution
assumption

Figure 10. Regression model with GPA as the IV and Use of Stimulants for Partying
or Getting High as the DV: Assessment of independence of errors assumption
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Figure 11. Regression model with GPA as the IV and Use of Stimulants for Partying
or Getting High as the DV: Assessment of homogeneity of variance and linearity
assumption

Figure 12. Regression model with GPA as the IV and Use of Stimulants for Partying
or Getting High as the DV: Assessment of normal distribution assumption
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Figure 13. Regression model with DASS subscales as the IV and Use of Stimulants for
Academic, Cognitive, Physical, or Social Enhancement as the DV: Assessment of
independence of errors assumption

Figure 14. Regression model with DASS subscales as the IV and Use of Stimulants
for Academic, Cognitive, Physical, or Social Enhancement as the DV: Assessment of
homogeneity of variance and linearity assumption
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Figure 15. Regression model with DASS subscales as the IV and Use of Stimulants
for Academic, Cognitive, Physical, or Social Enhancement as the DV: Assessment of
normality assumption

Figure 16. Regression model with DASS subscales as the IV and Use of Stimulants
for Partying or Getting High as the DV: Assessment of independence of errors
assumption
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Figure 17. Regression model with DASS subscales as the IV and Use of
Stimulants for Partying or Getting High as the DV: Assessment of homogeneity of
variance and linearity assumption

Figure 18. Regression model with DASS subscales as the IV and Use of
Stimulants for Partying or Getting High as the DV: Assessment of normality
assumption

90

Figure 19. Regression model with DASS subscales and ADHD symptoms as the IV
and Use of Stimulants for Academic, Cognitive, Physical, and Social Enhancement as
the DV: Assessment of independence of errors assumption

Figure 20. Regression model with DASS subscales and ADHD symptoms as the IV
and Use of Stimulants for Academic, Cognitive, Physical, and Social
Enhancement as the DV: Assessment of homogeneity of variance and linearity
assumption
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Figure 21. Regression model with DASS subscales and ADHD symptoms as
the IV and Use of Stimulants for Academic, Cognitive, Physical, and Social
Enhancement as the DV: Assessment of normality assumption

Figure 22. Regression model with DASS subscales and ADHD symptoms as the IVs
and Use of Stimulants for Partying or Getting High as the DV: Assessment of
independence of errors assumption
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Figure 23. Regression model with DASS subscales and ADHD symptoms as the
IVs and Use of Stimulants for Partying or Getting High as the DV: Assessment
of homogeneity of variance and linearity assumption

Figure 24. Regression model with DASS subscales and ADHD symptoms as the
IV and Use of Stimulants for Partying or Getting High as the DV: Assessment of
normality assumption
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Figure 25. Distribution of scores on the Use of Prescription Stimulants for Academic,
Cognitive, Physical, or Social Enhancement component of the SSQ

Figure 26. Distribution of scores on the Use of Prescription Stimulants for Partying
or Getting High component of the SSQ
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Appendix A
Informed Consent (English)
The University of Rhode Island
Department of Psychology
Prevalence of ADHD and Prescription Stimulant Misuse among College Students in
Iceland
PLEASE PRINT AND KEEP THIS FORM FOR YOURSELF
Dear Participant:
You have been invited to take part in a research project described below. If you have
any questions, please feel free to contact the student investigator, B. Gyda
Gudmundsdottir, at +1 (XXX) XXX-XXXX or XXX@my.uri.edu, or the principal
investigator, Dr. Lisa Weyandt, at +1 (XXX) XXX-XXXX or XXX@uri.edu.
The purpose of this study is to examine the misuse of prescription stimulant
medications among college students and how it relates to aspects of psychosocial
functioning, including symptoms of ADHD, depression, anxiety, and stress.
Responses to survey items are completely anonymous: there will be no identifying
information linking you to your responses. Data will be encrypted and stored through
the website SurveyMonkey, and only the primary student investigator will have access
to the data through the use of a password.
YOU MUST BE AT LEAST 18 YEARS OLD to participate in this research project.
If you are not, please discontinue the survey at this time.
If you decide to participate in this study, it will involve completing some
questionnaires pertaining to your perceptions about prescription stimulant medication,
symptoms of ADHD, depression, anxiety, and stress, and your demographic
background.
The possible risks of the study are minimal, although you may feel some
embarrassment answering questions of a personal nature. Please respond honestly, and
remember that your responses are anonymous.
Although there are no direct benefits of the study, your answers will help to increase
knowledge and understanding regarding the non-medical use of prescription
stimulants among college students.
Your participation in this study is anonymous. This means that your answers to all
questions are private. No one else can know that you participated in this study, and no
one can find out what your answers were to any items. Scientific reports will be based
on aggregated group data, and will not identify you or any individual in this project.
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The decision to participate in this research project is up to you. You do not have to
participate, and you can decline to answer the questionnaires. If you decide to take
part in the study, you may quit at any time. Whatever you decide will in no way
penalize you or your status as a student. Participation in this study is not expected to
be harmful or injurious to you.
If you have any additional questions or concerns about this study, you may contact the
student investigator, B. Gyda Gudmundsdottir, at +1 (XXX) XXX-XXXX, her faculty
sponsor, Dr. Lisa Weyandt, at +1 (XXX) XXX-XXXX, or the University of Rhode
Island’s Vice President for Research, 70 Lower College Road, Suite 2, URI, Kingston,
RI; +1 (XXX) XXX-XXXX.
By clicking this box, you are indicating that:
 You are at least 18 years old.
 You have read the consent form and your questions have been answered to
your satisfaction.
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Appendix A (continued)
Informed Consent (Icelandic)
UPPLÝST SAMÞYKKI
University of Rhode Island
Department of Psychology/Sálfræðideild
Algengi ADHD og misnotkunar örvandi lyfseðilsskyldra lyfja meðal háskólanema á
Íslandi [Prevalence of ADHD and Prescription Stimulant Misuse among College
Students in Iceland]
VINSAMLEGA GEYMIÐ EINTAK AF ÞESSU EYÐUBLAÐI TIL EIGIN
AFNOTA.
Kæri þátttakandi:
Þér hefur verið boðið að taka þátt í rannsókn sem lýst er hér að neðan. Vinsamlega
hafðu samband við rannsakendur, Bergljótu Gyðu Guðmundsdóttur, doktorsnema í
sálfræði, í síma +1 (XXX) XXX-XXXX eða gegnum tölvupóst: XXX@my.uri.edu,
eða leiðbeinanda hennar og ábyrgðarmann rannsóknarinnar, Dr. Lisu Weyandt, í síma
+1 (XXX) XXX-XXXX eða gegnum tölvupóst: XXX@uri.edu.
Markmið þessarar rannsóknar er að kanna misnotkun örvandi lyfseðilsskyldra lyfja
meðal háskólanema og hvernig slík hegðun tengist ýmsum sálfélagslegum breytum, til
dæmis einkennum athyglisbrests með ofvirkni (AMO; ADHD), þunglyndis, kvíða og
streitu. Svör við spurningum eru órekjanleg til einstakra þátttakenda og engum
persónuupplýsingum verður safnað. Gögn verða dulkóðuð og geymd á vefsíðu
SurveyMonkey og munu einungis rannsakendur hafa aðgang að gögnunum gegnum
notendanafn og lykilorð.
ÞÚ VERÐUR AÐ HAFA NÁÐ 18 ÁRA ALDRI til þess að taka þátt í rannsókninni.
Ef þú ert ekki orðin/-nn 18 ára, vinsamlega hættu þátttöku núna.
Ef þú ákveður að taka þátt í þessari rannsókn muntu verða beðin/-nn um að svara
spurningum um viðhorf þín til örvandi lyfseðilsskyldra lyfja, notkun slíkra lyfja, og
einkenna ADHD, þunglyndis, kvíða og streitu, sem og spurningum um bakgrunn þinn.
Áhætta af þátttöku í þessari rannsókn er nánast engin en þér gæti hugsanlega þótt
óþægilegt að svara spurningum er varða persónulega hagi þína. Vinsamlega svaraðu af
hreinskilni og mundu að svör þín eru nafnlaus og órekjanleg til þín.
Þótt enginn beinn ávinningur fáist af þátttöku í þessari rannsókn munu svör þín leiða
til aukinnar þekkingar og skilnings á misnotkun örvandi lyfseðilsskyldra lyfja meðal
háskólanema.
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Þátttaka þín í þessari rannsókn er nafnlaus. Það felur í sér að svör þín við öllum
spurningum eru leynileg. Enginn mun vita að þú hafir tekið þátt í þessari rannsókn og
enginn mun geta komist að því hverju þú svaraðir. Skýrslur og greinar um þessa
rannsókn munu byggjast á svörum þátttakenda í heild og ómögulegt verður að rekja
niðurstöður til einstakra þátttakenda.
Ákvörðun um þátttöku í þessari rannsókn er alfarið þín. Þér ber ekki skylda til að taka
þátt og þú mátt sleppa því að svara einstökum spurningum og/eða spurningalistum í
heild. Ef þú ákveður að taka þátt í rannsókninni máttu hætta þátttöku hvenær sem er.
Hver sem ákvörðun þín verður mun hún ekki hafa áhrif á stöðu þína sem háskólanemi
á nokkurn hátt. Þátttaka í þessari rannsókn telst áhættulaus.
Ef þú hefur einhverjar spurningar eða athugasemdir vegna rannsóknarinnar hafðu
vinsamlega samband við rannsakendur, Bergljótu Gyðu Guðmundsdóttur,
doktorsnema í sálfræði, í síma +1 (XXX) XXX-XXXX, eða leiðbeinanda hennar og
ábyrgðarmann rannsóknarinnar, Dr. Lisu Weyandt, í síma +1 (XXX) XXX-XXXX,
eða eftirlitsskrifstofu rannsókna við University of Rhode Island (University of Rhode
Island’s Vice President for Research), 70 Lower College Road, Suite 2, URI,
Kingston, Rhode Island, í síma +1 (XXX) XXX-XXXX.
Með því að merkja við hér að neðan staðfestir þú að:



Þú hefur náð 18 ára aldri.
Þú hefur lesið þetta eyðublað um upplýst samþykki og spurningum þínum
hefur verið svarað á fullnægjandi hátt.
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Appendix B
Debriefing (English)
The study that you just participated in examined misuse of prescription
stimulant medications among college students in Iceland, and the relationship between
ADHD symptoms, sex, GPA, depressive symptoms, anxiety, and stress among college
students. This study, titled, “Prevalence of ADHD and Prescription Stimulant Misuse
among College Students in Iceland” is being conducted in order to fulfill requirements
for a doctorate of philosophy degree in psychology.
The prevalence of misuse of stimulant medications among college students in
the United States has been well documented in research. This study is the first to
assess prevalence rates among Icelandic college students and to further examine risk
factors associated with stimulant misuse in this population. Results of this
investigation may help to identify sub-populations of Icelandic college students who
are at risk for misuse of stimulant medication, and to inform prevention and
intervention strategies designed to address prescription stimulant misuse.
If you have any questions or concerns about this study, please contact Bergljot
Gyda Gudmundsdottir at +1 XXX-XXX-XXXX or at xxx@gmail.com. Thank you
for your time and participation.
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Appendix B (continued)
Debriefing (Icelandic)
Rannsóknin sem þú varst að ljúka þátttöku í felst í því að kanna algengi
misnotkunar örvandi lyfseðilsskyldra lyfja meðal íslenskra háskólanema og samband
einkenna athyglisbrests með ofvirkni (AMO eða ADHD), kyns, meðaleinkunnar,
þunglyndiseinkenna, kvíða og streitu við misnotkun örvandi lyfseðilsskyldra lyfja
meðal íslenskra háskólanema. Þessi rannsókn, sem ber titilinn “Algengi ADHD
einkenna og misnotkunar örvandi lyfseðilsskyldra lyfja meðal háskólanema á Íslandi”
(“Prevalence of ADHD and prescription stimulant misuse among college students in
Iceland”), er hluti af doktorsverkefni Bergljótar Gyða Guðmundsdóttur í sálfræði við
University of Rhode Island í Bandaríkjunum.
Rannsóknir hafa ítrekað sýnt fram á að misnotkun örvandi lyfja eigi sér stað
meðal háskólanema í Bandaríkjunum. Þetta er fyrsta rannsóknin sem kannar algengi
misnotkunar örvandi lyfseðilsskyldra lyfja og þætti sem spá fyrir um slíka hegðun
meðal íslenskra háskólanema. Niðurstöður þessarar rannsóknar geta hjálpað til við að
skilgreina hvaða undirhópar íslenskra háskólanema eru líklegri til að misnota örvandi
lyfseðilsskyld lyf en aðrir og geta einnig veitt mikilvægar upplýsingar fyrir forvarnir
og inngrip á þessu sviði.
Ef einhverjar spurningar vakna eða ef þú sérð eitthvað athugavert við þessa
rannsókn, vinsamlega hafðu samband við Bergljótu Gyðu Guðmundsdóttur í síma +1
XXX-XXX-XXXX eða gegnum tölvupóst: xxx@gmail.com. Kærar þakkir fyrir að
gefa þér tíma til að taka þátt.
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Appendix C
Statement on Diversity in Research
This research project aimed to recruit participants of both sexes/genders and
those with and without disabilities, to increase the likelihood that findings would
equally apply to all individuals within the target population, i.e., college students in
Iceland, in accordance with the requirements of the Office of Research Compliance
and the Institutional Review Board. Given the racial/ethnic homogeneity of the
Icelandic population (Statistics Iceland, 2013), it was considered likely that a large
majority of participants would identify as White/Caucasian. In addition, because
approximately 4% of university students are registered as having a disability
(University of Iceland, 2013), the majority of participants were likely to identify as not
having a disability. No college student enrolled at any of the target universities was
excluded from participation; however, to be eligible for participation, participants
needed to be able to read and write in Icelandic.
References
Statistics Iceland. (2013). Population by origin and citizenship. Retrieved from:
http://statice.is/Statistics/Population/Citizenship-and-country-of-birth.
University of Iceland. (2013). [Total number of students enrolled at the University of
Iceland since the beginning]. Heildarskráning nemenda í Háskóla Íslands frá
upphafi. Retrieved from:
http://www.hi.is/adalvefur/heildarskraning_nemenda_i_haskola_islands_fra_u
pphafi_0
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Appendix D
Demographic Questionnaire (English)

1. Current age (in years): ___________
2. Sex:
Male
Female
Other: __________
3. Race/Ethnicity (please circle one):
White
Non-White
Other: _________
4. Degree Program in which you are enrolled (please choose one):
Not attending college/university
Bachelor’s Level
Master’s Level
Specialist Level
Doctoral Level
Other (please specify): ___________
5. What is your current GPA (on a scale of 0-10)? _______
6. Have you ever used prescription stimulant medication (e.g., Ritalin, RitalinUno, Concerta, Adderall, Vyvanse, etc.) that was not prescribed to you?
Yes

No

7. Have you ever been diagnosed with Attention-Deficit-Hyperactivity Disorder
(ADHD or ADD)?
Yes

No

8. If you answered “yes” to the previous question, with what
subtype/presentation of ADHD are you diagnosed?
Hyperactive/Impulsive Type
Inattentive Type
Combined Type
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Do not know
9. If you answered “yes” to the previous question, at what age were you first
diagnosed? _______
10. Are you currently taking stimulant medication that has been prescribed to
you by a doctor, including methylphenidate (e.g. Ritalin, Concerta, Metadate) or
amphetamine (Adderall, Dexedrine, Desoxyn, Vyvanse)?
Yes

No

11. If “yes” to question 10, have you ever used stimulant medication that was
prescribed to you in a way other than the manner it was prescribed (e.g. higher
or more frequent dosage, different method of ingestion)?
Yes

No

12. Do you currently have a disability?
Yes

No

13. If “yes” to the previous question 12, are you currently registered with the
Disabilities Support Services office at your university?
Yes
No
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Appendix D (continued)
Demographic Questionnaire (Icelandic)

Bakgrunnsspurningar
1. Aldur (í árum): __________
2. Kyn:
Karl
Kona
Annað: __________
3. Kynþáttur/uppruni (vinsamlega veldu eitt):
Hvítur (White)
Ekki hvítur (Non-White)
Annað (vinsamlega útskýrið): __________
4. Tegund náms sem þú ert skráð/-ur í (vinsamlega veldu eina):
Ekki skráð/-ur í háskóla
Grunnnám til bachelor gráðu
Framhaldsnám til meistara- eða annarrar sérfræðigráðu
Framhaldsnám til doktorsgráðu
Annað (vinsamlega útskýrið): ___________
5. Hver er núverandi meðaleinkunn þín (á kvarðanum 0-10)? _______
6. Hefur þú einhvern tíma notað örvandi lyfseðilsskyld lyf (t.d. Ritalin, RitalinUno, Concerta, Adderall o.fl.) sem var ekki ávísað til þín?
Já

Nei

7. Hefur þú einhvern tíma verið greind/-ur með athyglisbrest með (eða án)
ofvirkni (AMO; attention deficit/hyperactivity disorder; ADHD, ADD)?
Já

Nei

8. Ef þú svaraðir síðustu spurningu játandi, hvaða undirtegund AMO/ADHD
varst þú greind/-ur með?
Athyglisbrestur (Inattentive)
Hreyfiofvirkni og hvatvísi (Hyperactive/Impulsive)
Blönduð (Combined)
Veit ekki
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9. Ef þú svaraðir síðustu spurningu játandi, hvenær varstu greind/-ur (aldur í
árum)? _______
10. Tekur þú örvandi lyf sem hefur verið ávísað til þín af lækni, til dæmis
metýlfenídat (t.d. Ritalin, Ritalin-Uno, Concerta, o.fl.) eða amfetamínskyld lyf
(t.d. Adderall, Dexedrine, Desoxyn, Vyvanse)?
Já

Nei

11. Ef þú svaraðir síðustu spurningu játandi, hefur þú einhvern tíma notað
örvandi lyf sem var ávísað til þín á annan hátt en tilgreint var á lyfseðli (t.d. í
stærri eða fleiri skömmtum eða með öðrum leiðum en gegnum munn)?
Já

Nei

12. Býrð þú við fötlun af einhverju tagi?
Já

Nei

13. Ef þú svaraðir síðustu spurningu játandi, nýtur þú formlegrar
þjónustu/aðstoðar vegna fötlunar þinnar í háskólanum sem þú ert skráð/-ur í?
Já

Nei
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Appendix E
DSM-IV Checklist of Symptoms – Past 6 Months (English)

Indicate the number that best describes your behavior over the past 6 months.
0 = Never or rarely 1 = Sometimes 2 = Often 3 = Very Often
1. Fail to give close attention to details or make careless mistakes in my work. ____
2. Fidget with my hands or feet or squirm in my seat. ____
3. Have difficulty sustaining my attention in tasks or fun activities. ____
4. Leave my seat in situations in which remaining seated is expected. ____
5. Don’t listen when spoken to directly. ____
6. Feel restless ___
7. Don’t follow through on instructions and fail to finish work. ____
8. Have difficulty engaging in leisure activities or doing fun things quietly. ____
9. Have difficulty organizing tasks and activities. ____
10. Feel “on the go” or “driven by a motor.” ___
11. Avoid, dislike, or feel reluctant to engage in work that requires sustained mental
effort. ____
12. Talk excessively. ____
13. Lose things necessary for tasks and activities. ____
14. Blurt out answers before questions have been completed. ____
15. Easily distracted. ____
16. Have difficulty awaiting my turn. _____
17. Forgetful in daily activities. ____
18. Interrupt or intrude on others. _____
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Appendix E (continued)
DSM-IV Checklist of Symptoms – Childhood (English)

Indicate the number that best describes your behavior when you were a child, prior to
12 years of age.
0 = Never or rarely 1 = Sometimes 2 = Often 3 = Very Often
1. Fail to give close attention to details or make careless mistakes in my work. ____
2. Fidget with my hands or feet or squirm in my seat. ____
3. Have difficulty sustaining my attention in tasks or fun activities. ____
4. Leave my seat in situations in which remaining seated is expected. ____
5. Don’t listen when spoken to directly. ____
6. Feel restless ___
7. Don’t follow through on instructions and fail to finish work. ____
8. Have difficulty engaging in leisure activities or doing fun things quietly. ____
9. Have difficulty organizing tasks and activities. ____
10. Feel “on the go” or “driven by a motor.” ___
11. Avoid, dislike, or feel reluctant to engage in work that requires sustained mental
effort. ____
12. Talk excessively. ____
13. Lose things necessary for tasks and activities. ____
14. Blurt out answers before questions have been completed. ____
15. Easily distracted. ____
16. Have difficulty awaiting my turn. _____
17. Forgetful in daily activities. ____
18. Interrupt or intrude on others. _____
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Appendix E (continued)
DSM-IV Checklist of Symptoms – Past 6 Months (Icelandic)
Hegðunarmatskvarði fyrir fullorðna
Veldu það svar sem lýsir best hegðun þinni eins og hún var síðustu 6 mánuði.

Aldrei eða sjaldan = 0

Stundum = 1

Oft = 2

Mjög oft = 3

1. Huga illa að smáatriðum eða geri fljótfærnislegar villur í starfi eða námi. ____
2. Er mikið með hendur og fætur á hreyfingu eða á iði þegar ég sit. ____
3. Á erfitt með að halda athygli vakandi við verkefni eða tómstundaiðju. ____
4. Fer úr sæti mínu í aðstæðum þar sem ætlast er til að ég sitji kyrr. ____
5. Virðist ekki hlusta þegar talað er beint til mín. ____
6. Hreyfi mig óhóflega mikið í aðstæðum þar sem það á ekki við; ofvirk(ur); finnst ég
vera eirðarlaus.__
7. Fylgi ekki fyrirmælum til enda og tekst ekki að ljúka verkefnum. ____
8. Á erfitt með að vera hljóð(ur) þegar ég sinni tómstundaiðju. ____
9. Á erfitt með að skipuleggja verkefni og athafnir. ____
10. Er alltaf á ferðinni, eða „er eins og þeytispjald“.
11. Forðast verkefni (t.d. í vinnu eða heima) sem krefjast mikillar beitingar hugans.
____
12. Tala óhóflega mikið. ____
13. Týni hlutum sem eru nauðsynlegir til verkefna eða athafna. ____
14. Gríp fram í með svari áður en spurningum er lokið. ____
15. Er auðtrufluð(-aður). ____
16. Á erfitt með að bíða eftir að röðin komi að mér. _____
17. Er gleymin(n). ____
18. Gríp fram í eða ryðst inn í samræður eða athafnir annarra. _____
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Appendix E (continued)
DSM-IV Checklist of Symptoms – Childhood (Icelandic)
Hegðunarmatskvarði fyrir fullorðna
Veldur það svar sem lýsir best hegðun þinni eins og hún var fyrir 12 ára aldur.

Aldrei eða sjaldan = 0

Stundum = 1

Oft = 2

Mjög oft = 3

1. Huga illa að smáatriðum eða geri fljótfærnislegar villur í starfi eða námi. ____
2. Er mikið með hendur og fætur á hreyfingu eða á iði þegar ég sit. ____
3. Á erfitt með að halda athygli vakandi við verkefni eða tómstundaiðju. ____
4. Fer úr sæti mínu í aðstæðum þar sem ætlast er til að ég sitji kyrr. ____
5. Virðist ekki hlusta þegar talað er beint til mín. ____
6. Hreyfi mig óhóflega mikið í aðstæðum þar sem það á ekki við; ofvirk(ur); finnst ég
vera eirðarlaus.__
7. Fylgi ekki fyrirmælum til enda og tekst ekki að ljúka verkefnum. ____
8. Á erfitt með að vera hljóð(ur) þegar ég sinni tómstundaiðju. ____
9. Á erfitt með að skipuleggja verkefni og athafnir. ____
10. Er alltaf á ferðinni, eða „er eins og þeytispjald“.
11. Forðast verkefni (t.d. í vinnu eða heima) sem krefjast mikillar beitingar hugans.
____
12. Tala óhóflega mikið. ____
13. Týni hlutum sem eru nauðsynlegir til verkefna eða athafna. ____
14. Gríp fram í með svari áður en spurningum er lokið. ____
15. Er auðtrufluð(-aður). ____
16. Á erfitt með að bíða eftir að röðin komi að mér. _____
17. Er gleymin(n). ____
18. Gríp fram í eða ryðst inn í samræður eða athafnir annarra. _____
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Appendix F
Depression Anxiety Stress Scale -21 (DASS-21)
Lestu hverju fullyrðingu og veldu svar 0, 1, 2 eða 3 sem segir til um hve vel hver
fullyrðing átti við í þínu tilviki síðustu vikuna. Það eru engin rétt eða röng svör.
Eyddu ekki of miklum tíma í að velta fyrir þér hverri fullyrðingu.
[Please read each statement and circle a number 0, 1, 2, or 3 that indicates how much
that statement applied to you over the past week. There are no right or wrong
answers. Do not spend too much time on any statement].
0 = Átti alls ekki við mig. [Did not apply to me at all].
1 = Átti við mig að einhverju leyti eða stundum. [Applied to me to some degree, or
some of the time].
2 = Átti töluvert vel við mig eða drjúgan hluta vikunnar. [Applied to me to a
considerable degree, or a good part of time].
3 = Átti mjög vel við mig eða mest allan tímann. [Applied to me very much, or most of
the time].
1. Mér fannst erfitt að ná mér niður. [I found it hard to wind down]. ____
2. Ég fann fyrir munnþurrki. [I was aware of dryness of my mouth]. ____
3. Ég virtist alls ekki geta fundið fyrir neinum góðum tilfinningum. [I couldn’t seem to
experience any positive feeling at all]. ____
4. Ég átti í erfiðleikum með að anda (t.d. allt of hröð öndun, mæði án líkamlegrar
áreynslu). [I experienced breathing difficulty (e.g. excessively rapid breathing,
breathlessness in the absence of physical exertion)]. ____
5. Mér fannst erfitt að hleypa í mig krafti til að gera hluti. [I found it difficult to work
up the initiative to do things]. ____
6. Ég hafði tilhneigingu til að bregðast of harkalega við aðstæðum. [I tended to overreact to situations].____
7. Ég fann fyrir skjálfta (t.d. í höndum). [I experienced trembling (e.g. in the
hands)].____
8. Mér fannst ég eyða mikilli andlegri orku. [I felt that I was using a lot of nervous
energy]. ____
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9. Ég hafði áhyggjur af aðstæðum þar sem ég fengi hræðslukast (panic) og gerði mig
að fífli. [I was worried about situations in which I might panic and make a fool of
myself].___
10. Mér fannst ég ekki geta hlakkað til neins. [I felt that I had nothing to look forward
to]. ____
11. Ég var ergileg(ur). [I found myself getting agitated]. ____
12. Mér fannst erfitt að slappa af. [I found it difficult to relax]. ____
13. Ég var dapur/döpur og niðurdregin(n). [I felt down-hearted and blue]. ____
14. Ég þoldi ekki þegar eitthvað kom í veg fyrir að ég héldi áfram við það sem ég var
að gera. [I was intolerant of anything that kept me from getting on with what I was
doing]. ____
15. Mér fannst ég nánast gripin(n) skelfingu. [I felt I was close to panic]. ____
16. Ég gat ekki fengið brennandi áhuga á neinu. [I was unable to become enthusiastic
about anything]. ____
17. Mér fannst ég ekki vera mikils virði sem manneskja. [I felt I wasn’t worth much as
a person]. ____
18. Mér fannst ég frekar hörundsár. [I felt that I was rather touchy]. ____
19. Ég varð vör(var) við hjartsláttinn í mér þó ég hefði ekki reynt á mig (t.d. hraðari
hjartsláttur, hjartað sleppti úr slagi). [I was aware of the action of my heart in the
absence of physical
exertion (e.g. sense of heart rate increase, heart missing a beat)]. ____
20. Ég fann fyrir ótta án nokkurrar skynsamlegrar ástæðu. [I felt scared without any
good reason].____
21. Mér fannst lífið vera tilgangslaust. [I felt that life was meaningless]. ____
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Appendix G
Stimulant Survey Questionnaire (English)
Please answer the following questions about your college experience truthfully.
Stimulants refer to prescription medications including methylphenidate (Ritalin,
Concerta, Metadate) and amphetamine (Adderall, Dexedrine, Desoxyn).
Please circle the number that best describes your agreement with each statement.
These questions are rated on a Likert scale:
Never Rarely Occasionally Frequently Always
1. I have used prescription stimulants for non-medical purposes. 1
2
3
4
5
2. I have used prescription stimulants at parties.
1
3. I have used prescription stimulants with alcohol.
1
4. I have snorted prescription stimulants.
1
5. I have injected prescription stimulants.
1
6. I have smoked prescription stimulants.
1
7. I have taken prescription stimulants to focus better in class. 1
8. I have taken prescription stimulants to perform better on tests. 1
9. I have taken prescription stimulants to help me socialize better.1
10. I have taken prescription stimulants to help me lose weight. 1
11. I have taken prescription stimulants to perform
1
better in my school work.
12. I have taken prescription stimulants to feel more energetic.
1
13. I have taken prescription stimulants to feel better about myself.1
14. I have taken prescription stimulants to “get high”.
1
15. I have been offered prescription stimulants by other students. 1
16. I have tried someone else’s prescription stimulant medication. 1
17. I have purchased prescription stimulants from other students. 1
18. I have sold prescription stimulant medication to other students. 1
19. I have given prescription stimulant medication to other students.1
20. I have been pressured into letting someone else
1
have my prescription stimulant medication.

2
2
2
2
2
2
2
2
2
2

3
3
3
3
3
3
3
3
3
3

4
4
4
4
4
4
4
4
4
4

5
5
5
5
5
5
5
5
5
5

2
2
2
2
2
2
2
2
2

3
3
3
3
3
3
3
3
3

4
4
4
4
4
4
4
4
4

5
5
5
5
5
5
5
5
5

Please answer the following questions about your college experience truthfully.
Stimulants refer to prescription medications including methylphenidate (Ritalin,
Concerta, Metadate) and amphetamine (Adderall, Dexedrine, Desoxyn).
Please circle the number that best describes your agreement with each statement.
Strongly
These questions are rated on a Likert scale:
Disagree
Disagree Neutral
21. Prescription stimulants are easy to get on this campus.
1
2
3
22. Prescription stimulants are as easy to get as alcohol.
1
2
3
23. Prescription stimulants are as easy to get as marijuana.
1
2
3
24. Using prescription stimulants occasionally is harmless.
1
2
3
25. Using prescription stimulants daily is harmless.
1
2
3
26. Prescription stimulant use on campus is a problem.
1
2
3
27. Prescription stimulants are safer than marijuana.
1
2
3
28. Prescription stimulants are safer than alcohol.
1
2
3
29. I feel I am knowledgeable about prescription stimulants.
1
2
3
30. I feel I am knowledgeable about the side effects
1
2
3
of prescription stimulants.
Please Circle Yes or No to the following questions:
31. I know students who use prescription stimulants at parties.
32. I know students who use prescription stimulants with alcohol.
33. I know students who use prescription stimulants with other drugs.
34. I know students who use prescription stimulants while studying.
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YES
YES
YES
YES

Agree
4
4
4
4
4
4
4
4
4
4

NO
NO
NO
NO

Strongly
Agree
5
5
5
5
5
5
5
5
5
5

35. I know students who use prescription stimulants during finals week.
36. I know students who use prescription stimulants during tests.
37. I know students who snort prescription stimulants.
38. I know students who inject prescription stimulants.
39. I know students who smoke prescription stimulants.
40. I hide my prescription stimulant medication so that no one will take it.
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YES
YES
YES
YES
YES
YES

NO
NO
NO
NO
NO
NO

Appendix G (continued)
Stimulant Survey Questionnaire (Icelandic)
Vinsamlega svaraðu eftirfarandi spurningum hreinskilnislega. Miðað er við tímabilið frá því
háskólanám hófst. Þegar talað er um“örvandi lyfseðilsskyld lyf” er átt við lyf sem ávísað er
með lyfseðli, svo sem metýlfenídat, t.d. Ritalin, Ritalin-Uno, Concerta og skyld lyf (t.d.
Adderall, Vyvanse, Focalin o.fl.).
Vinsamlega veldu það svar sem á best við hverju sinni.
1. Ég hef notað örvandi lyfseðilsskyld lyf í öðrum
tilgangi en læknisfræðilegum.
2. Ég hef notað örvandi lyf þegar ég fer út að skemmta
mér eða “á djamminu”.
3. Ég hef notað örvandi lyfseðilsskyld lyf með áfengi.
4. Ég hef sniffað/snortað/sogið örvandi lyfseðilsskyld
lyf gegnum nefið.
5. Ég hef sprautað mig með örvandi lyfseðilsskyldum
lyfjum.
6. Ég hef reykt örvandi lyfseðilsskyld lyf.
7. Ég hef tekið örvandi lyfseðilsskyld lyf til auka
einbeitingu mína í tíma.
8. Ég hef tekið örvandi lyfseðilsskyld lyf til að
standa mig betur á prófum.
9. Ég hef tekið örvandi lyfseðilsskyld lyf til að eiga
auðveldara með samskipti við aðra.
10. Ég hef tekið örvandi lyfseðilsskyld lyf til að
grennast.
11. Ég hef tekið örvandi lyfseðilsskyld lyf til að
standa mig betur í námi
12. Ég hef tekið örvandi lyfseðilsskyld lyf til að
fá aukaorku.
13. Ég hef tekið örvandi lyfseðilsskyld lyf til að
bæta sjálfsálit mitt.
14. Ég hef tekið örvandi lyfseðilsskyld lyf til þess
að komast í vímu.
15. Aðrir nemendur hafa boðið mér örvandi
lyfseðilsskyld lyf.
16. Ég hef prófað örvandi lyfseðilsskyld lyf af
öðrum nemendum.
17. Ég hef keypt örvandi lyfseðilsskyld lyf af
öðrum nemendum.
18. Ég hef selt öðrum nemendum örvandi
lyfseðilsskyld lyf.
19. Ég hef gefið öðrum nemendum örvandi
lyfseðilsskyld lyf.
20. Ég hef orðið fyrir þrýstingi að gefa öðrum
örvandi lyf sem ávísað var til mín.
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Aldrei
1

Sjaldan
2

Stundum Oft
3
4

Alltaf
5

1

2

3

4

5

1
1

2
2

3
3

4
4

5
5

1

2

3

4

5

1
1

2
2

3
3

4
4

5
5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3
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4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

Vinsamlega svaraðu eftirfarandi spurningum hreinskilnislega.Þegar talað er um“örvandi lyf”
er átt við lyf sem ávísað er með lyfseðli, þ.m.t. metýlfenídat, t.d. Ritalin, Ritalin-Uno, Concerta
og skyld lyf (t.d. Adderall, Vyvanse, Focalin o.fl.).
Vinsamlega veldu það svar sem á best við hverju sinni.
Mjög
Mjög
Ósammála Ósammála Hvorki/né Sammála Sammála
21. Það er auðvelt að verða sér úti um örvandi
1
2
3
4
5
lyfseðilsskyld lyf í háskólasamfélaginu.
22. Það er jafnauðvelt að verða sér úti um
1
2
3
4
5
örvandi lyfseðilsskyld lyf og áfengi.
23. Það er jafnauðvelt að verða sér úti um örvandi
1
2
3
4
5
lyfseðilsskyld lyf og gras/marijúana
24. Það er óhætt að nota örvandi
1
2
3
4
5
lyfseðilsskyld lyf af og til.
25. Það er óhætt að nota örvandi
1
2
3
4
5
lyfseðilsskyld lyf daglega.
26. Notkun örvandi lyfseðilsskyldra lyfja er
1
2
3
4
5
vandamál í háskólasamfélaginu.
27. Örvandi lyfseðilsskyld lyf eru öruggari en
1
2
3
4
5
marijúana.
28. Örvandi lyfseðilsskyld lyf eru öruggari en áfengi. 1
2
3
4
5
29. Ég tel mig vel upplýsta/-n um örvandi
1
2
3
4
5
lyfseðilsskyld lyf.
30. Ég tel mig vel upplýsta/-n um aukaverkanir
1
2
3
4
5
örvandilyfseðilsskyldra lyfja.
Vinsamlega veldu JÁ eða NEI eftir því sem við á:
31. Ég veit um nemendur sem nota örvandi lyfseðilsskyld lyf þegar þeir
JÁ
fara út að skemmta sér.
32. Ég veit um nemendur sem nota örvandi lyfseðilsskyld lyf með áfengi.
JÁ
33. Ég veit um nemendur sem nota örvandi lyfseðilsskyld lyf með öðrum lyfjum. JÁ
34. Ég veit um nemendur sem nota örvandi lyfseðilsskyld lyf þegar þeir læra.
JÁ

NEI

35. Ég veit um nemendur sem nota örvandi lyfseðilsskyld lyf í prófum.
36. Ég veit um nemendur sem taka örvandi lyfseðilsskyld lyf (snorta/sniffa)
í nefið.
37. Ég veit um nemendur sem sprauta sig með örvandi lyfseðilsskyldum lyfjum.
38. Ég veit um nemendur sem reykja örvandi lyfseðilsskyld lyf.
39. Ég fel örvandi lyfseðilsskyld lyf sem var ávísað til mín fyrir öðrum
svo enginn taki þau.

JÁ
JÁ

NEI
NEI

JÁ
JÁ
JÁ

NEI
NEI
NEI
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NEI
NEI
NEI

